

05 APR 2001

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

PU3565USW

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/806840

INTERNATIONAL APPLICATION NO.

PCT/GB99/03286

INTERNATIONAL FILING DATE

October 5, 1999

PRIORITY DATE CLAIMED

October 5, 1998

TITLE OF INVENTION

CHEMICAL CONSTRUCTS

APPLICANT(S) FOR DO/EO/US

CARR et al.

CARR ROBIN ARTHUR ELLIS

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
- ☒ A copy of the International Search Report (PCT/ISA/210).
- ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
- ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
- ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
- ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

PCT/RO/I01

U.S. APPLICATION NO. (IF KNOWN)

09/806840

ATTORNEY'S DOCKET NUMBER

PU3565USW

21. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00
- ☒ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$690.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	49 - 20 =	29	x \$18.00	\$522.00
Independent claims	4 - 3 =	1	x \$80.00	\$80.00

Multiple Dependent Claims (check if applicable). ☐

\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$1,292.00

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐

\$0.00

SUBTOTAL =

\$1,292.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$1,292.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

\$0.00

TOTAL FEES ENCLOSED =

\$1,292.00

Amount to be:

refunded

\$

charged

\$

☐ A check in the amount of _____ to cover the above fees is enclosed.

☒ Please charge my Deposit Account No. **07-1392** in the amount of **\$1,292.00** to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **07-1392** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:



23347

PATENT TRADEMARK OFFICE

SIGNATURE

Frank P. Grassler

NAME

31,164

REGISTRATION NUMBER

4/5/2001

DATE

Page 2 of 2

PG3565USW

JC08 Rec'd PCT/PTO 05 APR 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: CARR et al.
International Application No.: PCT/GB99/03286
International Filing Date: 05 October 1999
Title: CHEMICAL CONSTRUCTS

Commissioner for Patents
Washington, DC 20231

FIRST PRELIMINARY AMENDMENT

Dear Sir:

12. (Amended) A chemical construct according to claim 1 wherein the group G is a basic amino group.
17. (Amended) A chemical construct according to claim 12 wherein the basic amino group is derived from the photochemical cleavage of a carbamate group.
18. (Amended) A chemical construct according to claim 3 wherein the peak splitting isotopic label is contained within a substituted or unsubstituted alkylene diamine group.
21. (Amended) A chemical construct according to claim 1 wherein the first cleavage site is selectively cleavable by one type of chemistry selected from a group of chemistries consisting of cleavage under acid conditions, base catalysed cleavage, oxidative cleavage, reductive cleavage, nucleophilic displacement, cleavage by 1,2 *bis* nucleophiles, electrophilic displacement, and thermal, photochemical and enzymatic cleavage, and the second cleavage site is selectively cleavable by a different type of chemistry selected from the said group.
24. (Amended) A chemical construct according to claim 21 wherein the first cleavage site is defined by a sulphonamide linker group, and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.
25. (Amended) A chemical construct according to claim 21 wherein the first cleavage site is defined by a thiopyrimidine linker susceptible to cleavage by oxidation followed by nucleophilic displacement, and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.
26. (Amended) A chemical construct according to claim 21 wherein the first cleavage site is defined by a dde group and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.
27. (Amended) A chemical construct according to claim 21 wherein the first cleavage site is cleavable under photochemical conditions and the second cleavage site is defined by a group, such as a Rink linker, which is cleavable under acid conditions.

05805840.072501

28. (Amended) A chemical construct according to claim 21 wherein the first cleavage site is defined by a group such as allyloxycarbonylamino that can be cleaved by a transition metal such as palladium (0), and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions
29. (Amended) A chemical construct according to claim 21 wherein the first cleavage site is cleaved by oxidation followed by nucleophilic displacement.
32. (Amended) A chemical construct according to claim 1 wherein the fragment Fr contains a chromophore C^u that facilitates analysis of the fragment Fr by ultraviolet, visible or fluorescence spectrophotometry.
35. (Amended) A chemical construct according to claim 1, the construct comprising a solid support Q having linked thereto via the connecting group Y the substrate R wherein the fragment Fr comprises the substrate and at least a portion of the connecting group Y, and the said portion contains a chromophore C^u which facilitates analysis of the fragment Fr^u by ultra violet, visible or fluorescence spectroscopy, the chromophore C^u having a principal log E_{max} value of at least 2.5 and wherein (i) the principal log E_{max} value is at least 1.5 times greater than the principal log E_{max} of the substrate R; or (ii) , the chromophore C^u has an absorption peak at a wavelength remote from absorptions due to the substrate R.
36. (Amended) A chemical construct according to claim 1 comprising a solid support Q having linked thereto via the connecting group Y the substrate R wherein the fragment Fr comprises the substrate and at least a portion of the connecting group Y, and the said portion contains a chromophore C^u which facilitates analysis of the fragment Fr^u by ultra violet, visible or fluorescence spectroscopy, wherein the absorption characteristics of the chromophore C^u and the substrate R are such that at a given measurement wavelength, any errors in measurement of the quantity of substrate R (or any fragment or construct containing the fragment) arising from any overlap between absorption bands due to the chromophore and absorption bands due to the substrate R are less than 10%, preferably less than 5%.
37. (Amended) A chemical construct according to claim 32 wherein the chromophore is a group containing an aryl group.

42. (Amended) A method of analysing the constructs of claim 1; the method comprising cleaving the construct at the first cleavage site to release the chemical fragment Fr, the cleavage reaction generating on the chemical fragment Fr at the cleavage site a group comprising a mass spectrometric sensitising group G (e.g. a group which is ionisable under mass spectroscopic conditions), and then subjecting the chemical fragment to mass spectrometry, e.g. electrospray mass spectrometry.

43. (Amended) An intermediate chemical construct for use preparing a chemical construct as defined in claim 1, the intermediate construct having the formula Q-Y' wherein Q' is a reactive or protected form of the group Q.

44. (Amended) An intermediate construct of the formula Q-L¹-A^p wherein Q and L¹ are as defined in claim 1 and A^p is a reactive or protected form of the spacer group containing a peak splitting isotopic label.


REMARKS

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information. The claims have been amended to place them in form appropriate to US practice.

Respectfully Submitted,

Date: 4/5/2001


Frank P. Grassler
Registration No. 31,164

GlaxoSmithKline
Five Moore Drive
PO Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-2482
Fax: 919-483-7988

ABSTRACT

CHEMICAL CONSTRUCTS

The invention provides a chemical construct for use in solid phase synthesis comprising a solid support Q having linked thereto via a connecting group Y a substrate R; the connecting group Y having first and second cleavage sites which are orthogonally and selectively cleavable; the second cleavage site being selectively cleavable to release the substrate; and the first cleavage site being located at a position between the second cleavage site and the solid support and being selectively cleavable to release a fragment Fr comprising the substrate and at least a portion of the connecting group Y; characterised in that cleavage at the first cleavage site forms or introduces on the chemical fragment Fr at the first cleavage site a moiety comprising a sensitising group G (such as an amino group) which sensitises the chemical fragment Fr to instrumental, e.g. mass spectroscopic, analysis. Also provided are methods of analysis employing the constructs, as well as intermediate constructs

1052/03430360

Version with markings to show changes made

5. (Amended) A chemical construct according to [any one of] claim[s] 2 [to 4] wherein the means for imparting a characteristic signature to the mass spectrum of the fragment is located between the first and second cleavage sites.
6. (Amended) A chemical construct according to [any one of the preceding claims] claim 1 wherein the first and second cleavage sites are defined by first and second linker groups L^1 and L^2 .
10. (Amended) A chemical construct according to [any one of the preceding claims] claim 1 wherein the sensitising group G is an ionisable group which is ionisable under mass spectrometric conditions.
12. (Amended) A chemical construct according to [any one of the preceding claims] claim 1 wherein the group G is a basic amino group.
17. (Amended) A chemical construct according to claim 12 [or claim 13] wherein the basic amino group is derived from the photochemical cleavage of a carbamate group.
18. (Amended) A chemical construct according to [any one of] claim[s] 3 [to 17] wherein the peak splitting isotopic label is contained within a substituted or unsubstituted alkylene diamine group.
21. (Amended) A chemical construct according to [any one of the preceding claims] claim 1 wherein the first cleavage site is selectively cleavable by one type of chemistry selected from a group of chemistries consisting of cleavage under acid conditions, base catalysed cleavage, oxidative cleavage, reductive cleavage, nucleophilic displacement, cleavage by 1,2 *bis* nucleophiles, electrophilic displacement, and thermal, photochemical and enzymatic cleavage, and the second cleavage site is selectively cleavable by a different type of chemistry selected from the said group.
24. (Amended) A chemical construct according to claim 21 [or claim 22] wherein the first cleavage site is defined by a sulphonamide linker group, and the second cleavage

site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.

25. (Amended) A chemical construct according to claim 21 [or claim 22] wherein the first cleavage site is defined by a thiopyrimidine linker susceptible to cleavage by oxidation followed by nucleophilic displacement, and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.

26. (Amended) A chemical construct according to claim 21 ~~or~~ claim 22 wherein the first cleavage site is defined by a dde group and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.

27. (Amended) A chemical construct according to claim 21 [or claim 22] wherein the first cleavage site is cleavable under photochemical conditions and the second cleavage site is defined by a group, such as a Rink linker, which is cleavable under acid conditions.

28. (Amended) A chemical construct according to claim 21 [or claim 22] wherein the first cleavage site is defined by a group such as allyloxycarbonylamino that can be cleaved by a transition metal such as palladium (0), and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions

29. (Amended) A chemical construct according to claim 21 [or claim 22] wherein the first cleavage site is cleaved by oxidation followed by nucleophilic displacement.

32. (Amended) A chemical construct according to [any one of the preceding claims] claim 1 wherein the fragment Fr contains a chromophore C^u that facilitates analysis of the fragment Fr by ultraviolet, visible or fluorescence spectrophotometry.

35. (Amended) A chemical construct according to [any one of] claim[s] 1 [to 34], the construct comprising a solid support Q having linked thereto via the connecting group Y the substrate R wherein the fragment Fr comprises the substrate and at least a portion of the connecting group Y, and the said portion contains a chromophore C^u which facilitates analysis of the fragment Fr^u by ultra violet, visible or fluorescence

spectroscopy, the chromophore C^u having a principal log E_{max} value of at least 2.5 and wherein (i) the principal log E_{max} value is at least 1.5 times greater than the principal log E_{max} of the substrate R; or (ii) , the chromophore C^u has an absorption peak at a wavelength remote from absorptions due to the substrate R.

36. (Amended) A chemical construct according to [any one of] claim[s] 1 [to 35] comprising a solid support Q having linked thereto via the connecting group Y the substrate R wherein the fragment Fr comprises the substrate and at least a portion of the connecting group Y, and the said portion contains a chromophore C^u which facilitates analysis of the fragment Fr^u by ultra violet, visible or fluorescence spectroscopy, wherein the absorption characteristics of the chromophore C^u and the substrate R are such that at a given measurement wavelength, any errors in measurement of the quantity of substrate R (or any fragment or construct containing the fragment) arising from any overlap between absorption bands due to the chromophore and absorption bands due to the substrate R are less than 10%, preferably less than 5%.

37. (Amended) A chemical construct according to [any one of] claim[s] 32 [to 36] wherein the chromophore is a group containing an aryl group.

42. (Amended) A method of analysing the constructs of [any one of the preceding claims] claim 1; the method comprising cleaving the construct at the first cleavage site to release the chemical fragment Fr, the cleavage reaction generating on the chemical fragment Fr at the cleavage site a group comprising a mass spectrometric sensitising group G (e.g. a group which is ionisable under mass spectroscopic conditions), and then subjecting the chemical fragment to mass spectrometry, e.g. electrospray mass spectrometry.

43. (Amended) An intermediate chemical construct for use preparing a chemical construct as defined in [any one of the preceding claims] claim 1, the intermediate construct having the formula Q-Y' wherein Q' is a reactive or protected form of the group Q.

44. (Amended) An intermediate construct of the formula Q-L¹-A^p wherein Q and L¹ are as defined in [any one of the preceding claims] claim 1 and A^p is a reactive or protected form of the spacer group containing a peak splitting isotopic label.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: CARR et al.
International Application No.: PCT/GB99/03286
International Filing Date: 05 October 1999
Title: CHEMICAL CONSTRUCTS

Commissioner for Patents
Washington, DC 20231

SECOND PRELIMINARY AMENDMENT

Dear Sir:

Please amend the application as follows:

Please replace the priority information on the first line of the specification after the Title, as follows:

--This application is filed pursuant to 35 U.S.C. §371 as a United States National Phase application of International Application No. PCT/GB99/03286 filed 5 October 1999, which claims priority from GB9821655.9 filed 5 October 1998.--

In the claims:

Please cancel claims 48 and 49 without prejudice or disclaimer thereto.

Please add the following claims:

50. A method of identifying a pharmaceutically useful substrate comprising preparing a library containing a plurality of chemical constructs as defined in claim 1, and subjecting the library to biological testing to identify biologically active substrates.

51. A method according to claim 50 that includes the further step of formulating a biologically active substrate thus identified with a pharmaceutically acceptable carrier to form a pharmaceutical composition.

09/806840, 07/2504

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made." Applicant respectfully requests the entry of the above preliminary amendment.

Examiner is invited and encouraged to contact the undersigned if such contact would facilitate prosecution of this application.

Respectfully Submitted,

Date:

7/25/01

Frank P. Grassler
Frank P. Grassler
Registration No. 31,164

GlaxoSmithKline
Five Moore Drive
PO Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-2482
Fax: 919-483-7988

PG3565USW

Version with markings to show changes

This application is filed pursuant to 35 U.S.C. §371 as a United States National Phase application of International Application No. PCT/GB99/03286 filed 5 October 1999, which claims priority from GB9821655.9 filed [10] 5 October 1998.

0906240, 072541
T. 05270, 042036

CHEMICAL CONSTRUCTS

5

Field of the Invention

10 This invention relates to chemical constructs for use in solid phase synthesis, and to methods of detecting and/or characterising the products of solid phase synthesis using the constructs.

Background of the Invention

15 Solid phase synthesis has been known for many years in the field of peptide synthesis and more recently has also been used increasingly for the synthesis of non-peptides.

20 Solid phase synthesis has found particular application in the field of combinatorial chemistry and the preparation of chemical libraries as potential sources of new leads for drug discovery, see for example Anthony W. Czarnik, *Analytical Chemistry News and Features*, June 1, 1998, pp 378A-386A, and *The Combinatorial Index*, Barry A. Bunin, Academic Press, San Diego 1998. A feature of combinatorial chemistry methods is that they enable very large numbers of different compounds to be prepared from a relatively limited number of molecular building blocks in a relatively small number of reactions. Combinatorial chemistry makes use of the "split and pool" approach in which a suspension of chemical starting material tethered to a solid support is split into N portions, each of which is reacted with a different reagent. The products of the N reactions are then pooled and mixed thoroughly, the resulting pool is split into N' portions and again each portion is reacted with a different reagent. This procedure can be repeated as many times as there are steps in the reaction sequence. Thus, for a three step reaction sequence, if the reaction mixture is divided into ten portions at each stage, each of the pools being reacted with a different reagent before recombining with the other portions, the total number of compounds formed by the process will be $10^3 = 1000$. Thus it can be seen that by using the split and pool technique, a large number of different molecules can be synthesised using a minimal number of reactions (thirty in the case mentioned above).

35

Each of the solid supports (e.g. a resin bead) will have a single product molecule

tethered to it and hence in principle each of the reaction products can be separated and analysed or subjected to biological testing simply by isolating each single solid support and cleaving the product from the support. However, the large numbers of compounds generated by combinatorial methods means that it can be impracticable to identify and characterise each compound. Consequently, the compounds usually are first tested, either on the solid support or after cleaving from the support, and only those compounds, which show some biological activity, are subsequently identified. In order to minimise the number of biological tests carried out, compounds can be tested in pools containing a predetermined number of compounds, the inactive pools being discarded and the active pools being subject to further investigation. The biological activities of the compounds can be analysed using high throughput automated assay techniques permitting large numbers of compounds to be analysed in a short time.

The resin beads typically used in the synthesis of combinatorial libraries are derived from cross-linked polystyrene resin and are usually of the order of 90µm and 250µm in diameter (i.e. just visible to the naked eye). The number of beads in a given mass or volume of resin will depend on the average bead size but, for example, with a bead size of 150µm diameter, there will be approximately 500 beads per milligram of bulk resin. Typical compound loadings on the beads are of the order of 0.1 to 0.4 mmol g⁻¹ and hence beads of the dimensions given above will tend to have individual compound loadings of about 1 nanomole of compound per bead. It will be appreciated therefore that one of the problems facing the chemist working with solid phase constructs is how to identify and characterise the various compounds in a combinatorial library since each compound may be present in the library in very small amounts, and there will usually be insufficient compound present on a given solid support to allow for both biological testing and identification of the compound.

One known approach to the problem of how to identify the compounds in a combinatorial library is to provide each solid support with a coding tag from which the identity of the compound can be determined. Thus, for example, a coding tag can be built up in sequential steps on the solid support in parallel with the construction of the desired target compound, the coding tag reflecting the synthesis history of the product compound and being unique for each product compound. The coding tag is usually built up on the support using chemical reactions of a type which are orthogonal to the chemistry used to build up the product compound, thereby ensuring that the coding units and product compounds do not become confused. Once the product compound has been tested, and its biological activity confirmed, the coding tag can then be decoded to allow identification of the compound.

In an alternative approach, as described in Geysen *et al.*, Chemistry & Biology, 1996, Vol. 3, No. 8, pp 679-688, and in WO 97/37953, coding tags such as isotopic labels can be incorporated into *inter alia* a linker group between the solid support and the substrate. This approach has the advantage that it does not require the formation of a separate coding tag using orthogonal chemistry and thereby reduces the overall number of synthesis steps involved.

A further problem facing the solid phase chemist is the difficulty in quantifying the products of a given reaction sequence. In any solid phase synthesis procedure, whether or not part of a combinatorial procedure, it is important to be able to determine the optimal conditions for a given reaction step in a series of steps. It is also important to be able to monitor the progress of a reaction so that it can be determined whether a particular reaction has gone to completion. This is particularly important in a multistage solid phase synthesis where the failure of a given stage to proceed to completion can lead to the formation of side products thereby complicating what is otherwise a relatively straightforward separation procedure. Where multiple products are formed in a given reaction step or sequence of steps, or where a given reaction step has not proceeded to completion, it can be extremely useful to have means of quantifying the reaction products, either in absolute terms, or in terms of the relative concentrations with respect to other reaction products. Where the products are produced in milligram quantities, quantitation can be carried out using a variety of instrumental techniques, for example nuclear magnetic resonance (nmr) spectroscopy. However, quantitation is much more difficult where the amount of product available for analysis may be as little as 1 nanomole.

Although both destructive and non-destructive analytical methods are known for determining the products of solid phase synthesis (see *The Combinatorial Index, idem*), one of the recognised problems with solid phase synthesis is that it is generally more difficult to monitor reactions carried out on solid supports than it is to monitor conventional solution phase reactions; see for example the Czarnik paper referred to above. This is particularly true with the products of combinatorial chemistry methods where there is a need to use rapid high throughput techniques to analyse the large numbers of compounds generated by such methods. Techniques such as mass spectrometry are potentially ideally suited as a means of providing high throughput analyses, but a substantial problem is that not all compounds produce a guaranteed response under mass spectrometric conditions. Indeed, many compounds are "invisible" to the so-called "soft" methods of mass spectrometry such as Matrix-Assisted Laser-Desorption Ionisation (MALDI) and Electrospray mass spectrometry which are intended to

detect molecular ions without causing significant fragmentation of the molecule. In this context, the term "soft " means mass spectral methods that give molecular ions and not merely fragments. One of the reasons for this is that under MALDI and electrospray conditions, many compounds, particularly peptides, do not ionise sufficiently well to give a detectable mass spectral response.

Geysen et al. (idem) address this problem by suggesting the introduction of a readily ionisable basic centre such as lysine into the linker, and further suggest that the basic centre could be quaternised by alkylation during work up in order to give a charged group which would sensitise the construct to mass spectrometric analysis. However, one drawback of this approach is the need to protect the amine group during the various synthesis steps and the consequent need to deprotect the amine group prior to analysis.

A development of the Geysen approach is disclosed in Carrasco *et al. Tetrahedron Letters*, 1997, 38, No. 36, pp 6331-6334. Carrasco's method involves the formation of a construct comprising a resin bead linked via a first linker group to a group, which the authors refer to as an "ionisation tag". The "ionisation tag" in turn is linked via a second linker group to a substrate. The first and second linker groups are orthogonally cleavable; i.e. they can be selectively cleaved using different chemistries.

In the specific example disclosed in Carrasco *et al.*, the first linker group is photochemically cleavable whilst the second linker group is chemically cleavable. The "ionisation tag" used by Carrasco is a tetrapeptide chain having the sequence (reading from the C-terminus) Gly-Phe-Lys-Ala, and having an N-(2-trimethylammonium)-acetyl group linked to the lysine. The purpose of the ionisation tag is twofold. Firstly, it provides an already ionised "sensitiser group" which enables the construct to be detected by matrix-assisted laser-desorption ionisation (MALDI) mass spectrometry, and secondly, it adds mass to the construct thereby enabling substrate molecules to be detected without being swamped or masked by low molecular weight peaks in the mass spectrum.

However, there are several significant potential problems with the Carrasco constructs and in particular the "ionisation tag" used in the construct. More particularly, it is envisaged that the quaternary ammonium sensitiser group will be incompatible with many of the types of chemistry that the chemist might wish to perform on the constructs. Thus, for example, the trimethylammonium group is potentially chemically reactive and, furthermore, the cationic group may function as an ion exchange centre and complex with anions.

Summary of the Invention

It is an object of the present invention to provide a means of monitoring chemical reactions on solid supports which avoids problems inherent in known methods and which provides a means of detecting and identifying the products of solid phase synthetic techniques using mass spectroscopy.

Accordingly, in a first aspect, the invention provides a chemical construct for use in solid phase synthesis comprising a solid support Q having linked thereto via a connecting group Y a substrate R; the connecting group Y having first and second cleavage sites which are orthogonally and selectively cleavable; the second cleavage site being selectively cleavable to release the substrate; and the first cleavage site being located at a position between the second cleavage site and the solid support and being selectively cleavable to release a fragment Fr comprising the substrate and at least a portion of the connecting group Y; characterised in that cleavage at the first cleavage site forms or introduces on the chemical fragment Fr at the first cleavage site a moiety comprising a sensitising group G which sensitises the chemical fragment Fr to instrumental, e.g. mass spectroscopic analysis.

In the constructs of the invention, the sensitising group G is formed or introduced by cleavage of the "skeleton" of the construct. This is in contrast with known constructs (see for example Carrasco *et al.*, *idem*), where the sensitising group is present throughout the synthesis of the substrate, or where the sensitising group is revealed by cleavage of a side chain or removal of a protecting group from a pendant sensitising group.

The sensitising group G renders the fragment Fr, and hence indirectly the substrate R, more sensitive to analysis by a given analytical technique, and in particular a mass spectrometric technique. Thus the sensitising group can be a group which is readily ionisable under the conditions encountered in a mass spectrometer, and in particular electrospray mass spectrometry, to afford a strong signal.

The ionisable sensitising group formed during the selective cleavage from the solid support of the chemical fragment Fr serves to ensure that the fragment is ionised sufficiently in the mass spectrometer to give a strong response. This overcomes a problem inherent in many molecules synthesised by solid phase methods where a suitable ionising group is not present and analysis by high throughput mass spectral techniques is problematical.

The ionisable group can be for example a basic amino group or a carboxylate group but preferably it is a basic amino group. It will be appreciated that the term "basic amino group" as used herein refers in particular to an amino group that is readily protonated.

5

The basic amino group can be a primary amino group, a secondary amino group, or a tertiary amino group. Where the basic amino group is a tertiary amino group, it can be for example, a cyclic amino group such as piperidino, piperazino, pyrrolidino, or morpholino, piperidino or piperazino (e.g. N-methylpiperazino) being presently preferred.

10

In accordance with the invention, a moiety comprising the sensitising group G, such as a basic amino group, is formed or introduced at the first cleavage site as the chemical fragment Fr (hereinafter referred to as the analytical fragment) is cleaved from the solid support. The advantage of forming the sensitising group G in this way is that it avoids the potential problem of a pre-existing or pre-formed sensitising group interfering with the chemistry of the construct. Moreover, it avoids the need to have the sensitising group independently protected thereby obviating the additional problem of de-protection, a requirement which could limit the types of chemistry available to the chemist for cleavage at the first and second cleavage sites. Thus, for example, if a protected pendant sensitising group were present, and for example the conditions required for de-protection involved the use of an acid such as trifluoroacetic acid, then this would effectively prevent the use of an acid labile cleavage site as the second cleavage site linking the substrate to the rest of the construct. The constructs of the invention avoid such problems.

The atoms or functional group making up the sensitising group G can be present in a masked form in the construct before cleavage of the fragment Fr from the resin, the cleavage conditions merely serving to unmask the sensitising group G. Alternatively, the atoms or functional group making up or containing the sensitising group G can be introduced at the cleavage site during the cleavage reaction. For example, where the sensitising group is a basic amino group, the nitrogen atom of the amino group can be present in the construct before cleavage, or it can be introduced during the cleavage reaction.

When the sensitising group G is introduced from an external source during the cleavage reaction, it can form part of a larger chemical moiety. For example, the group G can be introduced as part of a group X-G wherein X is the residue of a nucleophile or electrophile, for example a nitrogen or sulphur-based nucleophilic group, e.g. a group of the formula G-Alk-

Nuc wherein Alk is an alkylene group (e.g. a C₂₋₂₀ and preferably C₂₋₆ alkylene group) optionally interrupted by one or more heteroatoms selected from oxygen, nitrogen and sulphur, and Nuc is a nucleophile, such as an amine (e.g. NH or NR' where R' is a C₁₋₆ alkyl group) or a thiolate group., and Nuc is a nucleophile, such as an amine or a thiolate group.

5

It is preferred that the chemical fragment Fr contains a means for imparting a characteristic signature to the mass spectrum of the fragment. The signature can advantageously be provided by incorporating into the fragment a "peak splitting" isotopic label. The peak splitting isotopic label comprises at least one atom that exists in a number of stable isotopic forms. By isotopic labelling of one or more particular atoms in the fragment Fr such that a given atom is labelled with a mixture of isotopes, the mass spectra of the molecular ions will appear as a characteristic pattern, the precise pattern depending on the relative amounts of the individual isotopes. Thus, for example, if a given atom in the fragment Fr is labelled such that 50% of the atoms are of one isotopic form and 50% are of another isotopic form, the mass spectrum will show the molecular ion as a characteristic doublet in which the peaks are of approximately equal height.

10

15

The purpose of the peak splitting atom(s) is to provide a characteristic pattern that will characterise any peak in the mass spectrum originating from the analytical fragment Fr, thereby distinguishing such peaks from those due to extraneous materials.

20

Examples of atoms that can be used as isotopic peak splitting labels include ¹H/²H (D), ⁷⁹Br/⁸¹Br, ¹²C/¹³C, ¹⁴N/¹⁵N and ¹⁶O/¹⁸O.

25

The fragment Fr can contain a single peak splitting isotopic label or more than one such label. For example, the isotopic label can be a single bromine atom in which case the peak for the molecular ion of the analytical fragment Fr liberated following cleavage from the solid support will appear as a doublet. By introducing a second or subsequent peak splitting label(s), a more complex peak pattern will be produced for the molecular ion.

30

The isotopic peak splitting label(s) preferably is/are located between the first and second cleavage sites.

The first and second cleavage sites can be defined by first and second linker groups L¹ and L². A "spacer group" A can be interposed between the two linker groups L¹ and L², the spacer group A typically containing an isotopic peak splitting label. Accordingly, in one

35

preferred embodiment of the invention, there is provided a chemical construct as hereinbefore defined wherein the connecting group Y has the formula L^1-A-L^2 ; wherein L^1 is a first linker group defining the first cleavage site; A is a chemical group (the spacer group) containing a peak splitting isotopic label; and L^2 is a second linker group defining the second cleavage site.

5

The first and second cleavage sites are orthogonally and selectively cleavable; i.e. the conditions used to effect cleavage at one of the cleavage sites will not cleave the other. A wide variety of different types of cleavage reaction can be used, examples being reactions selected from acid catalysed cleavage, base catalysed cleavage, metal catalysed cleavage, oxidative
10 cleavage, reductive cleavage, nucleophilic displacement, cleavage by 1,2 *bis* nucleophiles, electrophilic displacement, and thermal, photochemical and enzymatic cleavage.

Examples of linker groups that can be selectively cleaved under photochemical conditions to reveal or introduce a sensitising group G (e.g. an amine group) include carbamate
15 groups such as *o*-nitrobenzylcarbamate groups in which initial cleavage takes place between the benzylic methylene group and the adjacent oxygen atom, followed by loss of carbon dioxide to give a basic amino group.

Examples of linker groups that can be cleaved by nucleophilic displacement (e.g. to
20 reveal or introduce a sensitising group G) include sulphonamide linker groups in which the aryl (e.g. phenyl) ring of the sulphonamide contains an electron withdrawing group such as a nitro group, preferably in the *ortho* position of the aryl ring (see for example Kay *et al.* Tetrahedron Letters - 1997, 38(39)). Cleavage of the linker between the amino and sulphonyl moieties can be effected by a nucleophile such as a thiol or thiolate nucleophile in the presence of a base
25 such as 1,8-diazobicyclo[5.4.0]undec-7-ene (DBU), morpholine or sodium carbonate. Further examples of groups that can be cleaved by nucleophilic displacement include mercaptopyrimidine-based "safety catch" linkers such as 5-carboxy-2-mercaptopyrimidine, where cleavage can be effected by reacting under oxidising conditions to generate a sulfoxide or sulphone linkage, followed by reaction with a nucleophilic amino group to form a 2-
30 aminopyrimidine. Such linkers can be cleaved, for example, by reaction with a cyclic amine such as piperidine or an N-substituted piperazine (e.g. N-methylpiperazine), or an amino group-containing thiolate nucleophile (e.g. dimethylaminoethylthiolate) after first oxidising with an oxidising agent, preferably a relatively mild oxidising agent such as a per-acid or an inorganic per-salt such as potassium peroxymonosulphate (e.g. "Oxone").

35

Either the first or second cleavage sites/linkers, or both, but preferably the first, can be of the

"safety catch" variety; i.e. the cleavage site or linker group must be chemically modified in a first step before it can be subjected to cleavage in a second step (for example to reveal or introduce the sensitising group G). An advantage of such an arrangement is that it prevents or significantly reduces the possibility of cleavage taking place inadvertently. One example of a "safety catch" mechanism involves oxidation of a functional group (e.g. the mercaptopyrimidine-based "safety catch" linker described above) in a first step, the oxidation serving to make the functional group more amenable to displacement by a nucleophile in a subsequent cleavage step. The nucleophile can vary considerably in structure. For example, in one embodiment, the nucleophile can be an amino group-containing nucleophile), the amino group participating in the nucleophilic displacement action such that the amino group (sensitising group G) is attached directly to the cleavage site. Alternatively, in another embodiment, the amino group (or other sensitising group) can be present in a group (e.g. a dialkylaminoalkyl-thiolate anion) containing another nucleophile such as a sulphur nucleophile that becomes attached to the cleavage site.

Another class of linker groups suitable for use in the constructs of the present invention is the class of linker groups that are cleavable by 1,2 *bis* nucleophiles such as hydrazines and hydroxylamines. Such *bis* nucleophiles can be used to cleave the bond between the nitrogen atom and adjacent carbon atom in certain enamine systems, for example enamine systems in which the enamine is conjugated to a carbonyl group. Examples of such groups are groups based on oxo-substituted cycloalkylidene rings such as the 1-[4,4-dimethyl-2,6-dioxo-cyclohexylidene]-ethyl (dde) group coupled to an amino nitrogen atom. The constructs are preferably set up such that the enamine system defines the first cleavage site, breaking of the bond between the nitrogen atom and adjacent carbon atom as described above revealing an amine group that functions as a mass spectrometric sensitiser.

Either the first or second, but preferably the first, cleavage sites can be defined by linker groups that are cleavable under the action of transition metals, preferably palladium (0). Examples of such linker groups include allyloxy carbonyl amino groups which, when cleaved, release an amine group capable of acting as a mass spectrometric sensitiser.

Examples of linkers that can be selectively cleaved under acidic conditions include appropriately substituted benzyloxycarbonyl groups and appropriately substituted diphenyl-methylamino groups, both of which can be cleaved by the action of trifluoroacetic acid.

Particular examples of acid cleavable linker groups are set forth in *The Combinatorial*

Index, Barry A. Bunin, Academic Press, San Diego 1998, the disclosure of which is incorporated herein by reference. Linkers of the "Rink" or "Knorr" type typically comprise an N-protected 1-amino-1,1-diphenylmethane moiety, the amino group when deprotected allowing attachment to a substrate, one of the phenyl rings being substituted for example with dimethoxy groups and the other having a carboxyalkoxy substituent providing a second point of attachment. Cleavage with TFA gives rise to a substrate compound having a terminal carboxamido group. Linkers of the "Wang" type typically contain a substituted phenoxyacetyl group, the acetyl group providing one point of attachment, and a benzylic hydroxyl group on the phenyl ring forming a second point of attachment. Esters can be formed between a carboxyl group of a substrate and the benzylic hydroxyl group, the ester groups being subsequently cleavable with TFA to release a substrate compound having a terminal carboxylate group.

Examples of linkers that can be selectively cleaved under basic conditions include groups containing ester linkages.

In one embodiment, there is provided a chemical construct as hereinbefore defined wherein the first cleavage site is selectively cleavable to form or introduce a sensitising group G (in particular an amino group) and the cleavage is effected by one type of chemistry selected from a group of chemistries consisting of cleavage under acid conditions, base catalysed cleavage, palladium (0) catalysed cleavage, oxidative cleavage, oxidation followed by nucleophilic displacement, reductive cleavage, nucleophilic displacement, cleavage by 1,2-bis nucleophiles, electrophilic displacement, and thermal, photochemical and enzymic cleavage, and the second cleavage site is selectively cleavable by a different type of chemistry selected from the said group.

Although groups that are cleavable under acidic conditions can be used to form the first cleavage site, it is currently preferred that the first cleavage site is stable to acidic conditions. However, the second cleavage site may advantageously be cleavable in acidic conditions.

30

In a preferred embodiment, the first cleavage site is cleavable to form or introduce the sensitising group G, the cleavage being effected by one type of chemistry selected from:

- (i) photochemical cleavage, e.g. photochemical cleavage of a carbamate group such as a nitrobenzylcarbamate group;
- (ii) oxidation followed by cleavage through nucleophilic displacement, for example oxidation of a thiopyrimidine followed by nucleophilic displacement

- by an amine (e.g. a secondary amine such as N-methyl piperazine);
- (iii) cleavage of a sulphonamide by nucleophilic displacement, for example by a thiolate nucleophile (e.g. mercaptoethanol in the presence of a strong base such as DBU);
- 5 (iv) cleavage of enamine groups (particularly those containing an enamine moiety conjugated to a carbonyl group; e.g. as 1-[4,4-dimethyl-2,6-dioxo-cyclohexylidene]ethyl amino) with a 1,2-*bis* nucleophile such as hydrazine or hydroxylamine or derivatives thereof; and
- (v) transition metal catalysed cleavage of allyloxycarbonylamino groups, for
10 example palladium (0) catalysed cleavage of allyloxycarbonylamino groups.

In the aforementioned preferred embodiment, the second cleavage site can be, for example, cleaved under acid conditions or by photolysis.

- 15 In one preferred embodiment, the first cleavage site is defined by a sulphonamide linker group, and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.

- 20 In another preferred embodiment, the first cleavage site is defined by a thiopyrimidine linker susceptible to cleavage by oxidation followed by nucleophilic displacement, and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.

- 25 In a further preferred embodiment, the first cleavage site is defined by a dde group as hereinbefore described, and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.

- 30 In a still further preferred embodiment, the first cleavage site is defined by a photochemically cleavable carbamate group as hereinbefore described, and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.

- In yet another preferred embodiment, the first cleavage site is defined by a group such as allyloxycarbonylamino that can be cleaved by a transition metal such as palladium (0), and the second cleavage site is optionally defined by a group, such as a Rink linker, which is
35 cleavable under acidic conditions

By making the first and second cleavage sites, e.g. as defined by the first and second linker groups L^1 , L^2 , orthogonally cleavable, it is possible selectively to separate from the construct either the chemical fragment Fr or the substrate R, simply by using different cleavage conditions. This means that during experiments designed to optimise the conditions for a particular reaction step, the chemist can subject the construct to conditions suitable for cleaving off the analytical fragment Fr thereby allowing analysis to be carried out to determine the outcome of each test reaction. Similarly, during a preparative reaction (e.g. preparation of a combinatorial library or subsequent preparative reactions such as scale-up reaction or commercial production), quality control (QC) can be carried out by removing one or more solid supports from the reaction vessel, cleaving the constructs at the first cleavage site and analysing the resulting fragment Fr to see whether a particular reaction step has worked. On the other hand, by cleaving at the second cleavage site e.g. on the second linker group, rather than the first, the reaction product R is released from the solid support. Thus, an advantage of the constructs of the present invention is that they can be used both at an experimental level to optimise a particular process step, and also at a preparative level without modifying the linker groups.

In one embodiment of the invention, the fragment Fr, and more preferably the spacer group A contains an alkylene diamine group or aminoalkoxy group. The precise size of the alkylene group and its degree of substitution is not currently considered to be important, but by way of example the chain could be from 2 to 30 carbon atoms in length, for example up to 20 carbon atoms, more typically less than 10 carbon atoms, particular examples being ethylene or propylene diamine or aminoalcohol groups which may be substituted or unsubstituted. The alkylene diamine group or aminoalcohol typically contains a peak splitting isotopic label as hereinbefore defined. The two amino groups can each be bonded to respectively the first and second linker groups. In order to increase the mass of the spacer group A, the alkylene diamine group can be substituted by an aryl group, for example an N-aryl group such as an N-benzyl group. The N-aryl group may optionally be substituted with one or more substituent groups.

Where, as is preferred, the spacer group contains one or more mass-spectral peak splitting isotopic labels, these can be located either in the alkylene chain or in a substituent group attached to the alkylene chain. Thus, for example, an N-benzyl group bonded to one of the two amino groups in an alkylendiamine can have a methylene group that is substituted with the peak splitting atom deuterium. Alternatively, an aryl ring (e.g. an N-benzyl group) present in a substituent on the alkylene diamine can be substituted with a peak splitting bromine atom, one particular example of an aryl group being an N-*o*-bromobenzyl group.

Although alkylene diamine and amino alcohol groups are given as specific examples of spacer groups, alternative spacer groups can be used. For example, the spacer groups can be formed from hydrocarbon chains containing up to thirty or more carbon atoms in the chain which can be optionally interrupted with one or more heteroatoms such as oxygen, nitrogen or sulphur. As a further alternative, the spacer can be for example a peptide chain containing one or more amino acids. The precise nature and length of the spacer is not currently considered to be important provided that the spacer does not interfere with the chemistry of the construct.

The chemical fragment Fr, and in particular the spacer group A, as well as providing a means of identification using mass spectrometry, can also be provided with one or more additional sensitisers to allow characterisation by other analytical techniques. For example, the spacer group can contain a chromophore to allow characterisation by ultra violet (u.v.) or fluorescence spectroscopy.

More particularly, in order to allow for quantitative analysis to be carried out to determine either the relative amount (e.g. relative to another substrate R) or absolute amount of substrate present in a reaction mixture, the connecting group Y and fragment Fr can contain a chromophore C^u which facilitates analysis of the fragment Fr by ultraviolet, visible or fluorescence spectrophotometry, and preferably by ultraviolet spectrophotometry.

Accordingly, in another aspect, the invention provides a method of analysis of a solid phase construct; which method comprises:

(i) providing a chemical construct comprising a solid support Q having linked thereto via a connecting group Y a substrate R wherein Q, Y and R are as hereinbefore defined; the connecting group Y having first and second cleavage sites which are orthogonally and selectively cleavable as hereinbefore defined; the second cleavage site being selectively cleavable to release the substrate; and the first cleavage site being located at a position between the second cleavage site and the solid support and being selectively cleavable to release a fragment Fr comprising the substrate and at least a portion of the connecting group Y, wherein the said portion contains a chromophore C^u which facilitates analysis of the fragment Fr^u by ultra violet, visible or fluorescence spectrophotometry (preferably UV spectrophotometry);

(ii) cleaving the connecting group at the first cleavage site to release the fragment Fr; and

(iii) subjecting the fragment Fr to ultra violet, visible or fluorescence spectrophotometric analysis to quantify the substrate R.

In accordance with the foregoing method aspect of the invention, the spectrophotometric analysis may be used to determine either the absolute amount of substrate R present in a given sample, or it may be used to determine the relative amount (e.g. in terms of a molar ratio) of substrate R present relative to another component (e.g. where more than one substrate R is present) in the sample. References to methods of quantifying the substrate R in this application include both absolute determination and relative determination, unless the context indicates otherwise.

In order to ensure that any chromophores present in the substrate R do not interfere with the analysis, the chromophore is typically selected such that it has a substantial absorption band that distinguishes it from the substrate. Thus, for example, the absorption band may be remote from any significant absorption bands in the substrate. Alternatively, the absorption band in the chromophore may be of such an intensity that it effectively swamps any overlapping band in the substrate. It is preferred that the chromophore C^u has a principal log E_{max} value of at least 2.5. It is further preferred that the principal log E_{max} value is at least 1.5 times greater than the principal log E_{max} of the substrate R.

The relationship between the absorption of visible or UV radiation by a compound in solution and the concentration of the compound is defined by the Beer-Lambert law which can be expressed by the formula $E = A/cl$ where A is the absorbance or optical density of a sample solution, c is the molar concentration, l is the path length of the sample, and E is the molar absorptivity. The molar absorptivity E is constant for a given compound at a given wavelength and is usually expressed as E_{max} - the molar absorptivity at an absorption band maximum. The values for E or E_{max} are typically expressed in units of $10^{-2} \text{ m}^2 \text{ mol}^{-1}$ and, unless indicated otherwise, references to E or E_{max} values herein will refer to such units. Since E or E_{max} values can be very large, the logarithmic equivalent is often used and such logarithmic equivalents are referred to herein as log E_{max} values.

A given compound will often have significant absorption peaks or bands at several different wavelengths and hence can often be defined with reference to several E_{max} values. In the context of the present invention, the term "principal E_{max}" is used to denote the E_{max} at the wavelength at which the greatest absorbance occurs. Thus, in the constructs of the present invention, the chromophore C^u preferably has a principle log E_{max} value of at least 2.5 and typically has a principal log E_{max} value which is at least 1.5 times greater than the principal E_{max} of the substrate R. More typically however, the chromophore C^u has a principal log E_{max} that is

at least 2, more usually 2.5, and preferably 3 times greater than the principal log E_{\max} of the substrate R.

Although analysis of the compounds can be effected by measuring absorbance at a principal maximum, measurement of side bands or lesser maxima may be used instead to determine the amount of compound present. In general, the wavelength at which the measurement is taken will depend on the precise absorption characteristics of the substrates R and the chromophore C^u , and can be determined on a case by case basis.

The chromophore C^u may be distinguished from any chromophores in the substrate R in that it may possess an absorption band which is remote from any significant absorption bands. By this is meant that the absorption band of the chromophore is remote from, and does not overlap to any significant extent (e.g. less than 5% overlap with respect to the area under the curve (a.u.c.) of the respective absorption peaks) with any significant absorptions due to the substrate R. A significant absorption in the present context means an absorption having a log E value of 1 or more.

In one preferred embodiment of the invention, there is provided a chemical construct for use in solid phase synthesis comprising a solid support Q having linked thereto via a connecting group Y a substrate R wherein Q, Y and R are as hereinbefore defined; and the connecting group Y is orthogonally and selectively cleavable as hereinbefore defined; wherein the fragment Fr comprises the substrate and at least a portion of the connecting group Y, and the said portion contains a chromophore C^u which facilitates analysis of the fragment Fr^u by ultra violet, visible or fluorescence spectroscopy, the chromophore C^u having a principal log E_{\max} value of at least 2.5 and wherein (i) the principal log E_{\max} value is at least 1.5 times greater than the principal log E_{\max} of the substrate R; or (ii), the chromophore C^u has an absorption peak at a wavelength remote from absorptions due to the substrate R.

The presence of a UV chromophore in the construct enables quantitation of the products of a synthesis to be carried out. Such quantitation can be (i) absolute quantitation or (ii) relative quantitation, or both. By absolute quantitation is meant that the absolute amounts of a substrate molecule or fragment or construct containing the substrate molecule can be determined, whereas the term "*relative quantitation*" is used herein to mean the determination of the amount of a substrate (or fragment or construct containing the substrate) relative to another component (such as a side product or starting material or another substrate) in a reaction mixture.

The UV chromophore is typically selected such that it has a very strong absorption at a unique or characteristic wavelength, which is usually distinct from the wavelengths at which the maximum absorbances of a typical substrate molecule might be found. However, in cases
5 where the absorption of the chromophore is very large relative to the substrate or substrate R, the overlapping of absorptions due to the substrate and the chromophore may have a minimal impact on the accuracy of the measurement of the quantity of substrate. In general, overlapping absorption bands should not prevent meaningful analyses to be carried out provided that any error introduced is no greater than 10% and preferably no greater than about 5%. Accordingly,
10 as an alternative to defining the chromophore in terms of relative absorbances and absolute molar absorption values, the chromophore C, and its relationship with the absorption due to the substrate can be defined in terms of the degree of error arising from any overlap between the absorption bands of the substrate R and the chromophore.

Thus, in a further embodiment, the invention provides a chemical construct for use in solid phase synthesis comprising a solid support Q having linked thereto via a connecting group Y a substrate R wherein Q, Y and R are as hereinbefore defined; and the connecting group Y is orthogonally and selectively cleavable as hereinbefore defined; wherein the fragment Fr comprises the substrate and at least a portion of the connecting group Y, and the said portion
20 contains a chromophore C^u which facilitates analysis of the fragment Fr^u by ultra violet, visible or fluorescence spectroscopy, wherein the absorption characteristics of the chromophore C^u and the substrate R are such that at a given measurement wavelength, any errors in measurement of the quantity of substrate R (or any fragment or construct containing the fragment) arising from any overlap between absorption bands due to the chromophore and absorption bands due to the
25 substrate R are less than 10%, preferably less than 5%.

Examples of chromophores are groups containing an aryl group, preferably a fused polycyclic aryl group, e.g. a C₆ - C₃₀ polycyclic aryl group in which one or more (e.g. 1, 2, or 3) ring carbon atoms are optionally replaced by a heteroatom such as nitrogen, sulphur or oxygen.
30 Examples of polycyclic aryl groups are polycyclic hydrocarbons such as naphthyl, phenanthrenyl and anthracenyl groups, and polycyclic heteroaryl groups such as acridine, or phenanthroline. Such aryl groups or polycyclic groups can be optionally substituted, preferably with a substituent or substituents which is or are inert and/or non-interfering with regard to the reaction conditions employed in a given reaction scheme.

35

Examples of such substituent groups include alkyl and alkoxy (e.g. alkyl and alkoxy

having from 1 to 20 carbon atoms, preferably from 1 to 6 carbons), each optionally containing one or more unsaturated linkages, and being optionally interrupted by one or more heteroatoms selected from oxygen, nitrogen and sulphur; amino (preferably protected amino or mono-or disubstituted amino, e.g. dimethylamino); halogen such as fluoro, chloro, bromo and iodo; 5 alkylthio (e.g. C₁₋₂₀ alkylthio, preferably C₁₋₆), hydroxy, protected (e.g. acylated) hydroxy, thio, protected (e.g. acylated) thio, trifluoromethyl, nitro, alkylsulphonyl, aryl (e.g. optionally substituted phenyl, thienyl, furanyl), and arylalkyl (e.g. benzyl and phenethyl).

Other examples of chromophores include highly conjugated aryl or non-aryl systems, 10 provided that such compounds are inert under the synthetic conditions employed in the solid phase chemistry, and so-called "push-pull" systems of the type G-J-M wherein G is an electron-donating group (e.g. amino or alkoxy), J is an conjugated array of multiple, e.g. double, bonds, and M is an electron withdrawing group (e.g. nitro or sulphonyl), the groups G and M being electronically linked through the conjugated array of multiple bonds. One example of such as 15 chromophore is the dansyl (1-dimethylamino-5-naphthylsulphonyl) group.

The precise nature of the chromophore, its chemical properties and its absorbance characteristics, can be determined on a case by case basis depending upon the type of chemistry 20 to be used in a given synthesis. It is most preferred however, that the chromophore is inert to the reactants and reaction conditions employed in the synthesis.

Presently preferred chromophores include anthracenyl and dansyl (5-dimethylamino-1-naphthylsulphonyl groups, anthracenyl being particularly preferred.

25 The quantitation of the substrate R can be either absolute quantitation or relative quantitation in which the relative amounts of the substrate R and another component in the synthesis mixture (e.g. another substrate, or starting material, or a side product for example) are determined. Relative quantitation makes use of the fact that the chromophore C^u confers on each substrate a common set of characteristic absorbances that can be used as the basis for the 30 spectrophotometric analysis.

In one embodiment of the invention, the characterisation and/or analysis of the constructs of the invention is carried out on a single bead, or a small number of beads, for example from 1 to 20 beads, more usually less than ten beads. Such beads typically have an 35 average diameter in the range from 90µm to 250µm and a compound loading of between 0.1 mmol g⁻¹ and 0.4 mmol g⁻¹ average loading of an individual bead is less than 10 nanomoles,

often less than 5 nanomoles, for example approximately 1 nanomole.

Accordingly, in one particularly embodiment, the invention provides a method of analysis of a solid phase construct; which method comprises:

- 5 (i) providing a chemical construct comprising a solid support Q (e.g. a resin bead having an average diameter in the range from 90 μ m to 250 μ m) having linked thereto via a connecting group Y a substrate R wherein Q, Y and R are as hereinbefore defined, the substrate R being present on each solid support in an amount of no more than 10 nanomoles, preferably less than 5 nanomoles and more preferably less than 2 nanomoles; the connecting group Y
10 having first and second cleavage sites which are orthogonally and selectively cleavable as hereinbefore defined; the second cleavage site being selectively cleavable to release the substrate; and the first cleavage site being located at a position between the second cleavage site and the solid support and being selectively cleavable to release a fragment Fr comprising the substrate and at least a portion of the connecting group Y, wherein the said portion contains
15 a chromophore C^u which facilitates analysis of the fragment Fr by ultra violet, visible or fluorescence spectrophotometry;
- (ii) isolating a solid support, or a plurality of solid supports not exceeding 20 in number (preferably less than 10, more preferably less than 5, e.g. 1 solid support);
- (iii) treating the solid support(s) to cleave the connecting group at the first
20 cleavage site to release the fragment Frⁿ containing the substrate R; and
- (iv) subjecting the fragment Frⁿ to ultra violet, visible or fluorescence spectrophotometric analysis to quantify the substrate R.

A significant advantage of the use of the UV chromophore-containing constructs of the
25 present invention is that they can be used to provide quantitative information on very small amounts of substrate compounds, for example amounts of the order of 1 nanomolar typically available from single resin beads of the size used in split and mix combinatorial methods. In combinatorial libraries formed by the split and mix method, each bead typically will contain only a single substrate compound, but a library will contain a plurality of beads bearing
30 different substrates. The analysis of mixtures of beads bearing different substrates is problematical and hence it is generally necessary to carry out analyses on single beads. The constructs of the present invention enable analysis to be carried out efficiently and accurately at the single bead level, and in particular with beads of a size of the order of 90 μ m to 250 μ m in diameter with loadings of the order of 0.1- 0.4 mmol g⁻¹.

35

In constructs where the first and second cleavage sites are defined by first and second

linker groups L^1 and L^2 , and a "spacer group" A is interposed between the two linker groups L^1 and L^2 , the spacer group A can contain or have linked thereto the UV chromophore C^u . Thus, in one embodiment of the invention, there is provided a chemical construct as hereinbefore defined wherein the connecting group Y has the formula L^1-A-L^2 ; wherein L^1 is a first linker group defining the first cleavage site; A is a chemical group (the spacer group) containing or having linked thereto the UV chromophore C^u , and optionally containing a peak splitting isotopic label; and L^2 is a second linker group defining the second cleavage site.

The chromophore C^u may be formed as an integral part of the backbone or skeleton of the fragment Fr^u (e.g. as part of the spacer group A), or it can be a pendant group. Thus, for example, when it is a pendant group, it can be linked to A either directly or via an alkylene chain (e.g. of 1 to 6 carbon atoms) optionally interrupted by one or more oxygen, nitrogen or sulphur atoms, or by means of an ether, thioether, amide, sulphonamide or ester linkage. Where the spacer group A contains an alkylene diamine group or aminoalkoxy group, the chromophore C^u can, for example, be linked (directly or via an optionally interrupted alkylene chain as hereinbefore defined) to the nitrogen atom of the, or one the, amino groups. For example, the chromophore C^u can be linked to the nitrogen atom by means of an ethylene or propylene chain or by a sulphonyl group.

In compounds where a substituent such as a benzyl group is attached to one of the amino groups of an alkylene diamine spacer group A, the chromophore C^u can be linked, directly or indirectly, to the other of the amino groups. In one currently preferred embodiment, the chromophore C^u is a polycyclic aryl group such as an anthracenyl or phenanthrenyl group linked via a propylene chain to a nitrogen atom at one end of the diamine spacer group.

The solid support Q can be any type of solid support suitable for use in solid phase synthesis, and in particular combinatorial chemistry. Thus, purely by way of example, the solid support can take the form of beads, a solid surface, solid substrates, particles, pellets, discs, capillaries, hollow fibres, needles, solid fibres, or organic or inorganic gels such as silica gels, and insoluble organic particles such as particles formed from fullerenes.

Examples of beads are polymeric beads such as cellulose beads or resin beads, particular examples of materials from which resin beads can be prepared including functionalised polymer resins such as polystyrene resins, polyacrylamide resins and dimethylacrylamide resins. Examples of suitable supports are listed in *The Combinatorial Index* by Barry A. Bunin, referred to above. Examples of functionalised resins include cross-

linked polystyrene resins modified to provide amino groups or hydroxyl groups at the surfaces thereof: see for example *Combinatorial Chemistry* by Nicholas K. Terrett, Oxford University Press, 1998.

5 In order to enable to simplify determination of the synthesis history of a solid support, and to provide a means of controlling the mixing of solid supports in split-and-pool combinatorial syntheses, the solid supports (e.g. groups of beads) can be confined within permeable labelled containers throughout a reaction sequence, whereby synthesis takes place as a result of the reactants and solvents flowing through the permeations in the container. A given
10 reaction mixture may contain a plurality of containers and, at the end of each reaction step, the containers can be removed and identified by the label which can be, for example, a radio frequency label. Examples of such containers are the polypropylene mesh "Kan"™ containers available from Irori of La Jolla, California, USA which contain miniaturised radio frequency tags.

15 In another aspect, the invention provides a method of analysing the constructs hereinbefore defined; the method comprising cleaving the construct at the first cleavage site to release the chemical fragment Fr, the cleavage reaction generating on the chemical fragment Fr a mass spectrometric sensitising group (e.g. a group which is ionisable under mass
20 spectroscopic conditions), and then subjecting the chemical fragment to mass spectrometry, e.g. electrospray mass spectrometry.

The analysis of the fragment Fr provides information on the reaction history of the construct. Thus, by mass spectrometric analysis, it can readily be determined whether or not
25 the desired substrate has been formed in a given reaction sequence. Analysis of the fragment Fr can therefore be used not only to characterise the substrate or product of the solid phase reaction sequence, but also to follow the progress of the reactions.

The invention also provides a method of analysing the constructs hereinbefore defined;
30 the method comprising cleaving the construct at the first cleavage site to release the chemical fragment F^u and subjecting the fragment to UV, visible or fluorescence spectrometric analysis, for example quantitative UV analysis.

The cleavage products can be subjected to chromatography, preferably a liquid
35 chromatography technique such as HPLC, using a UV detector which can be set up to provide a means of determining concentrations of the various compounds as they elute from the

chromatography column. The chromatography column can in turn be linked to another instrumental means of analysis for the purpose of identifying the substrate. A preferred means of instrumental analysis is mass spectroscopic analysis, and thus the method and constructs of the invention afford a means of means of achieving both identification and quantitation of the substrate in a single linked series of analytical procedures

In a further aspect, the invention provides an intermediate chemical construct for use preparing a chemical construct as hereinbefore defined, the intermediate construct having the formula Q-Y' wherein Y' is a reactive or protected form of the group Y, and Q and Y are as hereinbefore defined.

In a still further aspect, the invention provides an intermediate construct of the formula Q-L¹-A^p wherein Q and L¹ are as hereinbefore defined and A^p is a reactive or protected form of the spacer group A containing a splitting isotopic label and optionally a chromophore C^u. In a particular embodiment, the intermediate construct has the general formula Q-L¹-N(Alk - C^u)-Alk-NH-X¹ wherein Alk is an alkylene group and X¹ is hydrogen or an aralkyl group. The intermediate construct is preferably isotopically labelled with a peak splitting combination of atoms such as ¹H/²H (D), ⁷⁹Br/⁸¹Br, ¹²C/¹³C, ¹⁴N/¹⁵N and ¹⁶O/¹⁸O.

The invention further provides a method of identifying a pharmaceutically useful substrate comprising preparing a library containing a plurality of chemical constructs as hereinbefore defined and subjecting the library to biological testing to identify biologically active substrates. The method may include the further step of formulating a biologically active substrate thus identified with a pharmaceutically acceptable carrier to form a pharmaceutical composition.

Brief Description of the Drawings

Figure 1 shows the mass spectrum of the photolysis product of the construct described in Example 1;

Figure 2 shows the mass spectrum of a fragment produced by cleavage of the thiopyrimidine linker group in the construct described in Example 2;

Figures 3 to 8 show the mass spectra of the photolysis products of the constructs described in Example 4;

Figures 9 and 10 show the mass spectra of analytical fragments produced by palladium (0) cleavage of the "Alloc" - linker - containing constructs of Example 7; and

Figures 11 to 18 show the comparative mass spectra of either a substrate, or an analytical fragment containing the substrate, following cleavage at either the first or second cleavage sites for four of the members of the combinatorial library described in Example 6.

Description of Illustrative Embodiments

The invention will now be illustrated but not limited by reference to the following examples.

In the Examples, the following abbreviations are used.

Abbreviations

15	AcOH	Acetic acid
	DMF	Dimethylformamide
	DCM	Dichloromethane
	DMAP	4-Dimethylaminopyridine
	DIC	Diisopropylcarbodiimide
20	TFA	Trifluoroacetic acid
	DIPEA	Diisopropylethylamine
	HATU	2-(1H-9-Azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
	DMSO	Dimethylsulfoxide
25	PyBOP®	Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphoniumhexafluorophosphate
	HOBT	N-Hydroxybenzotriazole
	AA	Amino acid

EXAMPLE 1

Preparation of a Construct containing a Photolytically Cleavable First Cleavage Site

A photocleavable construct was prepared following the reaction scheme shown in Scheme 1. In this example, the photolytic cleavage of a substituted nitrobenzyloxycarbonyl linker group attached to one amino group of an ethylene diamine chain liberates the free amino group so that it is capable of undergoing ionisation in a mass spectrometer thereby enabling a

characteristic molecular ion to be formed. In this example, the ethylene diamine connecting group has an isotopically labelled benzyl group attached to the other amino group, the effect of which is to provide a characteristic split peak in the mass spectrum of the cleavage product to assist identification.


5

The compound numbers used in the Experimental for Example 1 refer to the compound numbers in Scheme 1.

P.03286-07890860

24

Scheme 1



Experimental For Scheme 1

TentaGel NH₂ (Rapp Polymere) (Resin 1) (30 g, 12.0 mmol), having a bead diameter in the range 130 µm to 160µm and a loading of 0.4 mmol g⁻¹, was swelled with DMF and to this
5 was added a solution of HOBT (9.3 g, 69.0 mmol), DIC (6.48 ml, 41.4 mmol) and 4-[4-(1-Hydroxyethyl)-2-methoxy-5-nitrophenoxy] butanoic acid (11.8 g, 39.4 mmol) in DMF (420 ml) and the mixture shaken for 16 h. The resin was then drained and washed with DMF followed by MeOH then DCM and finally MeOH. This was then dried *in vacuo* to give resin 2.

10 Resin 2 (3 g, 11.9 mmol) was treated with a solution of carbonyldiimidazole (19.3 g, 119 mmol) in DCM (400 ml) and the whole heated at 50 °C with slow stirring for 5 h. The resin was then drained and washed with DCM followed by Et₂O, DCM, Et₂O and dried *in vacuo* to give resin 3.

15 Resin 3 (15 g, 4.35 mmol) was swelled with DMF (200 ml) and to this was added a solution of 1-benzyl-1-*tert*-butoxycarbonyl-1,2-diaminoethane (17) (2.71 g, 10.9 mmol) and 1-(dideutero-benzyl)-1-*tert*-butoxycarbonyl-1,2-diaminoethane (16) (2.71 g, 10.9 mmol) in DMF (20 ml) and the whole heated at 50 °C with slow stirring for 16 h. The resin was drained and washed with DMF followed by Et₂O, DCM, and Et₂O. The resin was then dried *in vacuo*. The
20 resin was then treated with a 1:4 solution of aq.TFA (95%) and DCM and shaken for 30 min. The resin was then drained and washed with DCM followed by Et₂O, DCM, Et₂O and the resin was dried *in vacuo*. The resin was then shaken with 10% solution of DIPEA in DMF for 1h and then drained, the washing was then repeated as above to give resin 4.

25 A solution of HATU (0.96 g, 2.52 mmol), DIPEA (0.89 ml, 5.04 mmol) and p-[(R,S)-α-[1-(9H-fluoren-9-yl)-methoxyformamido]-2,4-dimethoxy-benzyl]-phenoxy-butanoic acid (1.42 g, 2.52 mmol) in DMF (30 ml) was added to Resin 4 (3 g, 0.84 mmol) and the whole shaken for 16 h. The resin was then drained and washed with DMF, and DCM. A solution of 20% piperidine in DMF (30 ml) was added to the resin and the whole shaken for 1h. The resin was
30 then drained and washed with DMF, DCM followed by Et₂O, DCM and Et₂O and the resin was dried *in vacuo*.

Resin 5 (20 mg, 0.004 mmol) was treated with a solution of HATU (15 mg, 0.04 mmol), DIPEA (14 µl, 0.08 mmol) and benzoic acid (5 mg, 0.04 mmol) in DMF (1 ml) and the

whole was shaken for 6 h. The resin was then drained and washed with DMF, DCM, Et₂O, DCM and Et₂O and dried *in vacuo* to give resin 6. Construct analysis of this resin by photocleavage followed by MS analysis is shown in figure 1 (see general cleavage conditions).

- 5 As can be seen from Figure 1, the presence of the sensitising amine group and peak splitter group in the analytical fragment cleaved from the resin to demonstrate a strong molecular ion with a characteristic doublet pattern.

General method of Construct Analysis of Resins via the photocleavable linker.

- 10 A small sample of the resin (ca. 0.5 mg) is suspended in DMSO (50 µl) and exposed to UV light for 30 min. The solution is then analysed by mass spectrometry. (Alternatively DMSO containing 0.2% hydrazine hydrate can be used as the solvent).


- The mass spectra were obtained on a Finnegan MAT LCQ ion trap Mass Spectrometer operating in positive electrospray mode. Scan range 100 -1500 a.m.u. Scan cycle time 1.4
15 seconds; ion time 200 microseconds

EXAMPLE 2

Preparation of a Construct Containing a "Safety Catch" Thiopyrimidine Linker Group at the First Cleavage Site

- 20 A construct containing a thiopyrimidine "Safety Catch" linker at the first cleavage site was prepared according to the reaction scheme shown in Scheme 2 below. The construct numbers used in the following experimental description refer to the numbers in Scheme 2.

Scheme 2



Experimental for Scheme 2

- 5 A solution of 4-(chloromethyl)benzoic acid (0.27 g, 1.6 mmol), PyBOP® (0.83 g, 1.6 mmol) and DIPEA (0.56 ml, 3.2 mmol) in DMF (8 ml) was shaken for 20 min then this solution was added to TentaGel NH2 (Rapp Polymere) resin 1 (1 g, 0.32 mmol), having a bead diameter in the range 130 µm to 160µm and a loading of 0.32 mmol g⁻¹, and the whole shaken for 5h. The resin was then drained and washed with DMF, DCM, Et₂O, DCM and finally Et₂O. The resin (8) was then dried *in vacuo*.
- 10 A slurry of thiourea (0.58 g, 7.7 mmol) in dioxane (4 ml) and ethanol (1 ml) was added to Resin 8 (1 g, 0.32 mmol) and the whole heated at 80 °C for 16h. The resin was drained and washed with DMF (x 5), DCM (x 5), Et₂O, DCM and finally Et₂O to give resin 9. The resin was then dried *in vacuo*.
- 15 A solution of methyl-2-(dimethylaminomethylene)-3-oxobutanoate (0.17 g, 0.96 mmol) and triethylamine (65 µl, 0.48 mmol) in DMF (10 ml) was added to resin 9 (1 g, 0.31 mmol) and the whole heated at 80 °C for 16h. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin (10) was then dried *in vacuo*.
- 20 Resin 10 (0.5 g, 0.15 mmol) was then treated with a 1:1 mixture of THF and 2N aq.NaOH (4 ml) and shaken for 2h. The resin was then drained and washed with THF/H₂O, 10% AcOH/THF, THF/H₂O, THF, DMF, DCM, Et₂O, DCM, Et₂O and then dried *in vacuo* to give resin 11.
- 25 A solution of PyBOP® (24 mg, 0.045 mmol) and DIPEA (16 µl, 0.09 mmol) in DMF (1 ml) was added to resin 11 (50 mg, 0.015 mmol) followed by a solution of 1-*tert*-butoxycarbonyl-1-(*o*-bromobenzyl)-diaminoethane (18) (15 mg, 0.045 mmol) in DMF (1 ml) and the whole shaken for 3 days. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. A solution of 95% aq.TFA in DCM (20%, 1 ml) was then added to the resin and shaken for 2h. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and then shaken with 10% DIPEA in DMF for 10 min. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin (12) was then dried *in vacuo*.
- 30
- 35 A solution of 4-[4-(1-(Fmoc-amino)ethyl)-2-methoxy-5-nitrophenoxy]butanoic acid (23 mg, 0.045 mmol), DIPEA (16 µl, 0.09 mmol) and HATU (17 mg, 0.045 mmol) in DMF (2 ml)

was added to resin **12** (50 mg, 0.015 mmol) and the whole shaken for 3h. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin was then treated with 20% piperidine in DMF (3 ml) and the whole shaken for 1h. The resin (**13**) was then drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O and dried *in vacuo*.

5

A solution of benzoic acid (11 mg, 0.09 mmol), DIPEA (16 µl, 0.09 mmol) and HATU (17 mg, 0.045 mmol) in DMF (2 ml) was added to resin **13** and the whole shaken for 2h. The resin (**14**) was then drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. Construct analysis of this resin by pyrimidine cleavage conditions (described below) followed by MS analysis is shown in figure 2.

10

General method of Construct Analysis of Resins via the Pyrimidine Linker.

A small sample of resin (ca. 0.5 mg) is treated with 0.01M m-chloroperbenzoic acid (0.5 ml) for 2h. The resin is then drained and washed with DCM, Et₂O and DCM. The resin is then treated with 0.02 M N-methylpiperazine in DMF (50 µl) is then added and shaken for 12h. The solution is then removed and analysed by mass spectrometry.


15

EXAMPLE 3

Preparation of Constructs Containing Different Peak Splitting Groups

20

A number of different mass spectrometric peak splitting groups have been prepared, and these are illustrated in Table 1 below.



R=	 16 / 17
	 18
	 19 / 20
	 21 / 22

Table 1

5 In Example 1, the peak splitting group was introduced by means of the mixture of deuterium labelled and unlabelled compounds 16/17 in Table 1 (see reference to resin 4) whereas in Example 2, the peak splitting group was introduced by means of the bromo-benzyl compound 18 (see reference to resin 12).

10 Resins containing alternative peak-splitting groups were prepared using the compounds 19/20 and 21/22 as described below.

Use of amines 19/20

15 A solution of 1-*tert*-butoxycarbonyl-1,2-diaminoethane (20) (110 mg, 0.68 mmol) and doubly ¹⁵N labelled 1-*tert*-butoxycarbonyl-1,2-di(¹⁵N)aminoethane (19) (112 mg, 0.68 mmol) in DMF was added to resin 3 (0.6 g, 0.18 mmol) and the whole heated at 50 °C for 3h. The resin was then drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin was then dried *in vacuo*.

Use of amines 21/22

A solution of 1-*tert*-butoxycarbonyl-1,5-diaminopentane (**21**) (295 mg, 1.45 mmol) and doubly ¹⁵N labelled 1-*tert*-butoxycarbonyl-1,2-di(¹⁵N)aminopentane (**22**) (295 mg, 1.45 mmol) in DMF was added to resin **3** (1.66 g, 0.58 mmol) and the whole heated at 50 °C for 4h. The resin was then drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. A solution of 95% aq.TFA in DCM (20%, 1 ml) was then added to the resin and shaken for 2h. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and then shaken with 10% DIPEA in DMF for 10 min. The resin (**23**) was then dried *in vacuo*.


10

EXAMPLE 4**Preparation of Constructs Containing Dipeptide Substrates**

In Examples 1 and 2, the substrate or target compound in each case is the model compound benzamide. In the following Examples, constructs were prepared containing dipeptides, as the substrate, bound to either a Rink linker or a Wang linker as the second linker group. In each case, a photocleavable first linker group was used. The reaction schemes used to prepare the constructs are shown in Schemes 3 and 4 below.


PCT/GB99/03286

Scheme 3



Scheme 4

5



Experimental for Amino acid examples**Preparation of Rink resin 24**

5

A solution of p-[(R,S)- α -[1-(9H-fluoren-9-yl)-methoxyformamido]-2,4-dimethoxybenzyl]-phenoxybutanoic acid (240 mg, 0.42 mmol), DIC (65 μ l, 0.42 mmol) and HOBT (57 mg, 0.42 mmol) in DMF (1 ml) was added to resin 23 (100 mg, 0.042 mmol) and the whole shaken for 4h. The resin was then drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin was then treated with 20% piperidine in DMF (2 ml) and shaken for 30 min. The resin (24) was then drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin was then dried *in vacuo*.

10

Preparation of Wang resin 27.

15

A solution of 4-formylphenoxyacetic acid (23 mg, 0.13 mmol), DIC (20 μ l, 0.13 mmol) and HOBT (17 mg, 0.13 mmol) in DMF (1 ml) was added to resin 23 (100 mg, 0.042 mmol) and the whole shaken for 4h. The resin was then drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin was then dried *in vacuo*. The resin was then treated with a solution of tetrabutylammonium borohydride (50 mg, 0.2 mmol) in DCM and shaken for 16h. The resin (27) was then drained and washed with DCM, DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin was then dried *in vacuo*.

20

Preparation of acylated dipeptide sequence on resin.

25

	RINK (25)			WANG (28)	
	AA1	AA2		AA1	AA2
Example 25a	Gly	Ala	Example 28a	Gly	Ala
Example 25b	Val	Gly	Example 28b	Val	Gly
Example 25c	Ala	Val	Example 28c	Ala	Val

Table 2: AA1 and AA2 on Rink and Wang linkers

The resins **25** and **28** were prepared by reacting the resins **24** and **27** respectively with the desired Fmoc protected amino acids followed by deprotection and then repeated coupling to the second aminoacid and deprotection (see general method). The terminal amino groups were
5 then acylated using acetic anhydride (see method below).

Construct analysis of these resins by photocleavage followed by MS analysis gave the mass spectra shown in the figures according to table 3.

Analysed Resin	Figure
25a	3
25b	4
25c	5
28a	6
28b	7
28c	8

Table 3: Mass spectra after construct analysis

General/Typical Method for coupling the amino acids to the linkers

A solution of the Fmoc protected amino acid (0.14 mmol, 10 Eq), DIC (22 μ l, 0.14 mmol, 10 Eq) and HOBt (19 mg, 0.14 mmol, 10 Eq) in DMF (1ml) was added to required resins 24 and 27 (30 mg, ca. 0.014 mmol). The whole was then shaken for 5h. The resin was then drained and washed with DCM, DMF, DCM, Et₂O, DCM, and finally Et₂O. The Fmoc protecting groups were then be removed by the treatment of the resins with 20% piperidine solution in DMF (2 ml) and shaking for 30 min. The resin was then drained and washed with DCM, DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin was then dried *in vacuo*.

Acetylation of the dipeptides

A solution of acetic anhydride (15 ml, 0.14 mmol) in DCM (1 ml) was added to the resins (30 mg, ca. 0.014 mmol) followed by DMAP (1 mg, 0.008 mmol) and the whole shaken for 2h. The resin was then drained and washed with DCM, DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin was then dried *in vacuo*.


As can be seen from the above examples, the constructs of the invention enable small molecules formed by solid phase methods to be analysed readily and easily by mass spectrometry. By providing an ionisable group as a mass spectral sensitiser, and a peak splitting isotope, the result in each case has been a readily interpreted mass spectrum in which the molecular ion appears as a characteristic doublet, and in which peaks due to fragments or extraneous materials are negligible.

EXAMPLE 5**Preparation of a Construct Containing a Sulphonamide Linker at the First Cleavage Site**


A construct containing benzoic acid as a model substrate linked via an acid labile "Rink" type linker to an ethylene diamine mass spectral peak splitting group and in turn via a sulphonamido linker to a resin was prepared as shown in Scheme 5 below. In this Example, cleavage of the sulphonamide with mercaptoethanol in the presence of strong base releases an analytical fragment having a mass spectrometric sensitising amino group

Scheme 5

5




38

Preparation of Compound 3a

5

To a stirred solution of 2-nitro-4-methylbenzoatesulfonyl chloride **1** (1.10 g, 3.90 mmol) and triethylamine (0.39 g, 3.90 mmol) in dry dichloromethane (40 ml), was added at 0°C the amine **2a** (1.00 g, 3.9 mmol) in dry dichloromethane (20 ml) over 30 min. The reaction mixture was stirred for a further 2 h at room temperature then concentrated *in vacuo* to give a yellow oil. Purification by chromatography with [MTBE:hexane (1:1)] as eluant followed by recrystallisation from MTBE (5 ml) and hexane (2 ml) furnished *the sulfonamide 3a* (1.53 g, 79%) as white flakes; mp 129-130°C; R_f 0.31 [MTBE:hexane (1:1)]; (Found: C, 53.2; H, 5.6; N, 8.5; S, 6.4. $C_{22}H_{25}D_2N_3O_8S$ requires C, 53.3; H, 5.5; N, 8.5; S, 6.5%); δ_H (DMSO- d_6) 1.40 (9H, s, H-18), 3.05 (2H, m, H-9), 3.20 (2H, dt, J 3 and 13, H-10), 3.9 (3H, s, O-Me), 7.10-7.35 (5H, m, H-13, 14 and 15), 8.09 (1H, d, J 8, H-6), 8.35 (1H, d, J 8, H-5), 8.40 (1H, m, H-8), 8.45 (1H, s, H-3); δ_C (DMSO- d_6) 27.8 (C-18), 40.9 (C-9 and 10), 45.9 (C-11), 53.0 (O-Me), 79.1 (C-17), 124.8 (C-13), 127.0 (C-14 and 15), 128.3 (C-6), 130.0 (C-13), 132.9 (C-5), 134.2 (C-12), 136.4 (C-1), 147.5 (C-4), 154.7 (C-2), 163.5 (C-16 and C=O); MS (Electrospray +ve) m/z 496 (MH)⁺; HPLC, R_t 6.07 min.


20

Preparation of Compound 4a

5

The ester **3a** (0.40 g, 0.80 mmol) in methanol (2 ml) was treated with 1M aqueous sodium hydroxide (1.60 ml, 1.60 mmol) and stirred at room temperature for 1 hour. The reaction was then concentrated *in vacuo* and the residue dissolved in water (10 ml) then acidified with 1M hydrochloric acid (1.80 ml, 1.80 mmol) at 0°C. The resulting white precipitate was extracted with dichloromethane (3 x 10 ml). The combined organic extracts were washed with brine, dried (Na₂SO₄) and evaporated under reduced pressure to *the acid 4a* (0.34 g, 88%) as a white solid; mp 143-145°C; R_F 0.58 [MTBE:hexane (1:1)]; δ_H (DMSO-d₆) 1.29 (9H, s, H-18), 3.02 (2H, m, H-9), 3.20 (2H, dt, *J* 3 and 13, H-10), 7.10-7.40 (5H, m, H-13, 14 and 15), 8.06 (1H, d, *J* 8, H-6), 8.28 (1H, s, H-3), 8.30 (1H, d, *J* 8, H-3); δ_C (DMSO-d₆) 27.9 (C-18), 40.9 (C-9 and 10), 45.9 (C-11), 79.1 (C-17), 124.5 (C-13), 127.1 (C-14 and 15), 128.4 (C-6), 129.5 (C-13), 132.5 (C-5), 139.2 (C-12), 147.3 (C-1), 155.1 (C-4), 164.8 (C-16 and C=O); (Found: MH⁺, 482.156364 C₂₁H₂₃D₂N₃O₈S requires MH⁺, 482.156615); HPLC, R_t 5.65 min.

20

Preparation of Compound 3b


5

To a stirred solution of 2-nitro-4-methylbenzoatesulfonyl chloride **1** (1.10 g, 3.90 mmol) and triethylamine (0.39 g, 3.90 mmol) in dry dichloromethane (40 ml), was added at 0°C the amine **2b** (0.95 g, 3.9 mmol) in dry dichloromethane (20 ml) over 30 min. The reaction mixture was stirred for a further 3 h at room temperature then concentrated *in vacuo* to give a yellow oil. Purification by chromatography with [MTBE:hexane (1:1)] as eluant followed by recrystallisation from MTBE (5 ml) and hexane (2 ml) furnished *the sulfonamide 3b* (1.51 g, 79%) as white flakes; mp 131-132°C; R_f 0.28 [MTBE:hexane (1:1)]; (Found: C, 53.7; H, 5.4; N, 8.4; S, 6.5. $C_{22}H_{27}N_3O_8S$ requires C, 53.5; H, 5.5; N, 8.5; S, 6.5%); δ_H (DMSO- d_6) 1.38 (9H, s, H-18), 3.10 (2H, t, J 8, H-9), 3.24 (2H, t, J 8, H-10), 3.95 (3H, s, O-Me), 4.32 (2H, s, H-11), 7.13-7.32 (5H, m, H-13, 14 and 15), 8.09 (1H, d, J 8, H-6), 8.29 (1H, s, H-3), 8.32 (1H, d, J 8, H-3); δ_C (DMSO- d_6) 28.3 (C-18), 40.2 (C-9 and 10), 46.2 (C-11), 53.2 (O-Me), 79.3 (C-17), 125.1 (C-13), 127.2 (C-14 and 15), 128.6 (C-6), 130.3 (C-13), 133.1 (C-5), 134.4 (C-12), 136.6 (C-1), 147.6 (C-4), 163.7 (C-16 and C=O); MS (Electrospray -ve) m/z 492 (M-H)⁻; HPLC, R_t 5.99 min.


25

Preparation of Compound 4b

5




The ester **3b** (0.40 g, 0.80 mmol) in methanol (2 ml) was treated with 1M aqueous sodium hydroxide (1.60 ml, 1.60 mmol) and stirred at room temperature for 1 hour. The reaction was then concentrated *in vacuo* and the residue dissolved in water (10 ml) then acidified with 1M hydrochloric acid (1.80 ml, 1.80 mmol) at 0°C. The resulting white precipitate was extracted with dichloromethane (3 x 10 ml). The combined organic extracts were washed with brine, dried (Na₂SO₄) and evaporated under reduced pressure to *the acid 4b* (0.36 g, 93%) as a white solid; mp 123.7-124.8°C; R_F 0.59 [MTBE:hexane (1:1)]; δ_H (DMSO-d₆) 1.42 (9H, s, H-18), 3.12 (2H, m, H-9), 3.22 (2H, m, H-10), 4.38 (2H, s, H-11), 7.18-7.42 (5H, m, H-13, 14 and 15), 8.11 (1H, d, *J* 8, H-6), 8.39 (1H, d, *J* 8, H-3); 8.45 (1H, s, H-3); δ_C (DMSO-d₆) 27.8 (C-18), 40.1 (C-9 and 10), 45.9 (C-11), 79.1 (C-17), 124.8 (C-13), 126.9 (C-14 and 15), 128.4 (C-6), 129.9 (C-13), 132.9 (C-5), 135.8 (C-12), 137.9 (C-1), 147.5 (C-4), 153.9 (C-2), 163.7 (C-16 and C=O); MS (Electrospray -ve) m/z 478 (M-H)⁻; HPLC, R_t 5.56 min.

Preparation of Compound 5

5

To a suspension of amine resin (Argogel-NH₂) (0.37 g, 0.15 mmol), having an average bead diameter of 150 μm and a loading of 0.4 mmol g⁻¹, in DMF (4 ml) and dichloromethane (2 ml) was added the benzoic acid (**4a**) (0.22 g, 0.45 mmol), and the benzoic acid (**4b**) (0.22 g, 0.45 mmol), followed by PyBOP (0.47 g, 0.9 mmol) and HOBT (0.12 g, 0.90 mmol) followed, 4 min. later by Hünig's base (0.21 g, 1.80 mmol). The reaction was agitated with nitrogen for 18 h and the resin then washed with dichloromethane (6 x 10 ml), DMF (6 x 10 ml), dichloromethane (6 x 10 ml), ether (2 x 10 ml) and dried *in vacuo* to give the **sulfonamide resin 5** (0.43 g, 97%) as a yellow solid; Kaiser test was negative; Bromophenol Blue test was negative.

Preparation of Compound 6


5

The protected resin (0.39 g, 0.13 mmol) was suspended in dichloromethane (2 ml) and treated with trifluoroacetic acid (2 x 4 ml) for 5 min. Solvents were removed by filtration and the resin washed with 10% DIPEA solution in DMF (3 x 5 ml), dichloromethane (6 x 5 ml), DMF (6 x 5 ml), dichloromethane (6 x 5 ml), ether (2 x 5 ml). The amine resin was then suspended in DMF (4 ml) and dichloromethane (2 ml) the Rink acid (0.51 g, 0.90 mmol) was added, followed by PyBOP (0.47 g, 0.9 mmol) and HOBt (0.12 g, 0.90 mmol). After 4 min. Hünig's base (0.21 g, 1.80 mmol) was added. The reaction was agitated with nitrogen for 18 h and the resin then washed with dichloromethane (6 x 10 ml), DMF (6 x 10 ml), dichloromethane (6 x 10 ml), ether (2 x 10 ml) and dried *in vacuo* to give the **sulfonamide resin 6** (0.43 g, 100%) as a yellow solid; Kaiser test was negative; Bromophenol Blue test was negative; Resin loading 98% as estimated by quantitative Fmoc group cleavage.

20

25

44

Preparation of Compound 7


5

Resin (**6**) (0.20 g, 0.06 mmol) was treated with 20% Piperidine in DMF solution (2 x 3 ml) for 10 min. Solvents were removed by filtration and the resin washed with DMF (6 x 3 ml), dichloromethane (6 x 3 ml), ether (2 x 3 ml). The resin was suspended in DMF (1 ml) and dichloromethane (1 ml) and benzoic acid (12 mg, 0.01 mmol) was added, followed by PyBOP (52 mg, 0.1 mmol) and HOBT (13 mg, 0.1 mmol). After 4 min. Hünig's base (26 mg, 0.2 mmol) was added. The reaction was agitated with nitrogen for 3 h and the resin then washed with dichloromethane (6 x 1 ml), DMF (6 x 1 ml), dichloromethane (6 x 1 ml), ether (2 x 1 ml) and dried *in vacuo* to give the **sulfonamide resin 7** (51 mg, 100%) as a yellow solid; Kaiser test was negative; Bromophenol Blue test was negative;

15

090649-01390660

45

Preparation of Compound 8

5

A small sample of resin (7) (ca. 0.5 mg) was treated with deprotecting solution A (0.5 ml) for 1 hr. The resin was filtered and the resulting solution was then analysed by electrospray mass spectrometry; MS (Electrospray -ve) m/z 582/584 (M-H)⁻; HPLC, R_t 4.49 min.

10

Solution A: Mercaptoethanol (0.23 ml, 3.0 mmol) and DBU (0.67 ml, 4.5 mmol) in MeCN (3 ml).

EXAMPLE 515 **Preparation of a Construct Containing a dde-linker at the first Cleavage site**

A construct containing a benzoic acid model substrate linked via a "Rink" type linker to an ethylene diamine mass spectral peak splitter and thence via a "dde" linker to a resin was prepared according to the reaction scheme set out in Scheme 6 below. Cleavage of the

20 construct at the first cleavage site defined by the dde group using hydrazine generates an analytical fragment having a free amino group as a mass spectrometric sensitising group.

9

10

11

12


13

14


15

R = 1:1 1H:2H

HPLC was run on a Hewlett Packard 1050 instrument using a C₁₈ reverse phase column (Supelco, Supelcosil ABZ+, 3.3 mm, 4.6 mm ϕ). Method A: 10 to 95% solvent B gradient (1 ml/min) as the mobile phase. [Solvent A: 1% TFA in water; solvent B; 0.5% TFA in MeCN:water (10:1), 8 min gradient time], or method B: C₁₈ reverse phase column (Dynamax 60A, 25 mm, 6 mm ϕ) with 10 to 95% solvent B gradient (1 ml/min) as the mobile phase. [Solvent A: 1% TFA in water; Solvent B; 0.5% TFA in MeCN:water (10:1), 10 min gradient time]. Melting points were performed on a Mettler FP5 automatic melting point apparatus in open tubes heating from 50°C at 2°C min⁻¹ and are uncorrected.

Preparation of Compound 10

- 5 4-Dimethylaminopyridine (4.03 g, 33 mmol) was added to a solution of adipic acid monoethylester (5.33 ml, 30 mmol) in dimethylformamide (50 ml) followed by diisopropylcarbodiimide (5.17 ml, 33 mmol). After 25 min, a solution of dimedone (4.63 g, 33 mmol) in dimethylformamide (25 ml) was added and stirring continued for 48 h. The reaction mixture was diluted with ethyl acetate (300 ml) and washed with 0.5M KHSO₄ (2 x 100 ml),
- 10 water (100 ml) and saturated brine (50 ml), then dried (MgSO₄), filtered and evaporated. The resulting slurry was triturated with ethyl acetate (250 ml), filtered and the residue washed with ethyl acetate. Evaporation of the combined filtrates gave a yellow gum which was purified by solid phase extraction (1.5" x 4" column, eluant: dichloromethane) to give **compound 10** as a yellow oil (7.43 g, 84%). δ_H (CDCl₃, 400MHz): 4.04 (q, 2H, H₂, 7 Hz), 2.97 (t, 2H, H₄, 7.5 Hz), 2.46 (s, 2H, H₁₃), 2.28 (s, 2H, H₁₄), 2.26 (d, 2H, H₇, 7.5 Hz), 1.60 (m, 4H, H_{5,6}), 1.00 (s, 6H, H₁₆). δ_C (CDCl₃, 400 MHz): 205.15 (C-12), 197.58 (C-11), 195.08 (C-3), 173.47 (C-8), 112.02 (C-10), 60.27 (C-2), 52.67 (C-4), 46.80 (C-13), 40.04 (C-14), 34.15 (C-7), 30.72 (C-15), 28.23 (C-16), 24.64 (C-5), 24.01 (C-6), 14.31 (C-1). ν_{max} (cm⁻¹): 2960 (OH), 1734 (C=O ester), 1665 (C=O ketone), 1564, 1445, 1143. MS: (electrospray +ve) m/z 297 (MH)⁺ (electrospray -
- 15 ve), 295 (M-H)⁻. HPLC method A: 5.31 min, 97%. 254nm.
- 20


Preparation of Compound 11

- 25 2M sodium hydroxide solution (2 ml, 4 mmol) was added to a solution of compound 10 in tetrahydrofuran (5 ml). After 3 h, the reaction mixture was poured onto 10% aq. hydrochloric acid (50 ml) and extracted with ethyl acetate (2 x 50 ml). The combined organic phases were dried (MgSO₄), filtered and evaporated to give **compound 11** as an off white solid

48

(498.5 mg, 95%). δ_H (CDCl₃, 400MHz): 2.99 (dd, 2H, H₂, 5 Hz), 2.47 (s, 2H, H₁₀), 2.34 (dd, 2H, H₅, 5Hz), 2.29 (s, 2H, H₁₁), 1.63 (m, 4H, H_{3,4}), 1.00 (s, 6H, H_{13,14}). δ_C (CDCl₃, 400 MHz): 205.15 (C-9), 197.58 (C-8), 195.08 (C-1), 173.47 (C-6), 112.02 (C-7), 52.96 (C-2), 47.11 (C-10), 40.40 (C-11), 33.92 (C-5), 30.72 (C-12), 28.23 (C-13,14), 24.64 (C-3), 24.01 (C-4). ν_{max} (cm⁻¹): 3030 (acid OH), 1702 (acid C=O), 1646 (ketone C=O). Melting point: 58.2°C. MS: (electrospray +ve) m/z 269 (MH)⁺ (electrospray -ve), 267 (M-H)⁻. HPLC method A: 4.15 min, 97%. 254nm.


Preparation of Compound 12



10


A solution of *N*-(*tert*-butoxycarbonyl)-*N*-benzyldiaminoethane (187.3 mg, 0.75 mmol) and *N*-(*tert*-butoxycarbonyl)-*N*-(α -dideutero)benzyldiaminoethane (189.3 mg, 0.75 mmol) in dichloromethane (3 ml) followed by diisopropylethylamine (348.4 μ l, 2 mmol) was added to a solution of compound 11 (268.4 mg, 1 mmol) in dichloromethane (2 ml). After stirring for 20 h, the reaction mixture was evaporated, redissolved in ethyl acetate (25 ml) and washed with 10% citric acid solution (3 x 10 ml), water (10 ml) and saturated brine (10 ml). The organic phase was dried (MgSO₄), filtered and evaporated then purified by flash chromatography (1 to 3% methanol in chloroform) to give **compound 12** as a yellow gum (474.5mg, 95%). δ_H (CDCl₃, 400MHz): 13.50 (bs, 1H, H₂₀), 7.30 (m, 5H, H₁₇), 4.45 (bd, 1H, H₁₈), 3.47 (bd, 4H, H_{15,16}), 2.90 (m, 2H, H₂), 2.40 (t, 2H, H₅, 7.4Hz), 2.30 (s, 4H, H_{10,11}), 1.75 (m, 2H, H₄), 1.45 (m, 11H, H_{3,19}). ν_{max} (cm⁻¹): 3030 (acid OH), 1730 (C=O, Boc, acid), 1690 (ketone C=O), 1570 (conj. enamine). MS: (electrospray +ve) m/z 503, 501 (MH)⁺ (electrospray -ve), 502, 499 (M-H)⁻. HPLC method A: 5.35 min, >97%. 230, 254nm.

25

Preparation of Compound 13

R = 1H:2H 1:1

- To a solution of compound 12 (310 mg, 0.62 mmol) in dichloromethane (6 ml) was added 1-hydroxybenzotriazole (110.8 mg, 0.82 mmol) and PyBOP (426.6 mg, 0.82 mmol). After 5 min, the solution was added to a suspension of aminomethyl Argogel® (500 mg, 0.205 mmol, 0.41 mmol/g loading) having an average bead size of 150µm, in dichloromethane (1 ml). The reaction mixture was agitated for 5 min then diisopropylethylamine (285.7µl, 1.64 mmol) was added and agitation continued for 16 h. The resin was washed with DMF (5 x) and DCM (5 x) then dried *in vacuo* to give *resin 13* (573.5 mg). The resin gave a negative bromophenol blue test.

Preparation of Compound 14

R = 1:1 1H:2H


FmocNH OMe

- Resin 13 (475.5 mg) was swollen with dichloromethane then treated with a solution of phenol (60 mg) in dichloromethane (1ml) followed by trifluoroacetic acid (3ml). The reaction mixture was agitated for 10 min then drained and washed with dichloromethane (2 x). The reaction was repeated then the resin washed with dichloromethane (1 x), 20% diisopropylethylamine in dimethylformamide (3 x), dimethylformamide (5 x) and dichloromethane (5 x) to give the amino resin intermediate which gave a positive bromophenol blue. The resin was suspended in dichloromethane (2 ml) and treated with a preformed solution of the C-4 Rink acid (351.5 mg, 0.62 mmol), 1-hydroxybenzotriazole (110.8 mg, 0.82 mmol) and PyBOP (426.6 mg, 0.82 mmol) in dimethylformamide (2 ml). After 5 min,

diisopropylethylamine (285.7 μ l, 1.64 mmol) was added and the reaction mixture agitated for 3 h after which the resin gave a negative bromophenol blue test. The resin was washed with DMF (5 x) and DCM (5 x) then dried *in vacuo* to give **resin 14** (500.9 mg).

- 5 A small sample of resin 14 (ca. 0.5 mg) was treated with 2% hydrazine in dimethylformamide for 30 minutes. The solution was then analysed by electrospray mass spectrometry to give an ion 700/702.

Preparation of Compound 15



10

- Resin 14 (65 mg) was treated with 20% piperidine in dimethylformamide (2 x 3 ml x 10 min) then washed with dimethylformamide (5 x) and dichloromethane (5 x). The resin gave a positive Kaiser test and was suspended in dichloromethane (1 ml) then treated with a preformed solution of benzoic acid (127 mg, 1.04 mmol), 1-hydroxybenzotriazole (140 mg, 1.04 mmol) and PyBOP (541 mg, 1.04 mmol) in dimethylformamide (2 ml). After 5 min, diisopropylethylamine (541 mg, 2.08 mmol) was added and the reaction mixture agitated for 72 h after which the resin gave a negative Kaiser test. The resin was washed with DMF (5 x) and DCM (5 x) then dried *in vacuo* to give **resin 15** (60 mg).

- 20 A small sample of the resin (ca. 0.5mg) was treated with 2% hydrazine in dimethylformamide for 30 minutes. The solution was then analysed by electrospray mass spectrometry to an ion 582/584.

EXAMPLE 6**Preparation of a 64-Membered Library By a 4x4x4 Combinatorial Synthesis**


The usefulness of the constructs of the invention in creating combinatorial libraries was demonstrated by preparing a 64 membered library of constructs containing different diamide substrates using a 4x4x4 combinatorial synthetic procedure. In order to provide a means of determining the synthesis history of the beads, and to enable sorting and mixing of the beads to be positively controlled (rather than being determined merely by simple statistical distribution) so that all 64 members of the library were formed, quantities of the resin beads were loaded into 64 radio frequency labelled Irori MicroKan TM containers. The MicroKan TM containers, available from Irori, of La Jolla, California, USA, are polypropylene containers having a polypropylene mesh side wall, a resin capacity of up to 30 mg and an internal volume of 330 µl. The use of the MicroKan TM containers provides the benefits, in terms of numbers of compounds synthesised, of a split and pool combinatorial synthesis, but avoids the need to build up coding constructs on the resin beads since the MicroKan TM containers are provided with radio-frequency tags which enable each container to be identified and therefore monitored through the reaction sequence. Consequently, since each container contains a unique substrate at the end of the reaction sequence, and the synthesis history of the container has been tracked, the identity of the substrate in each container can be determined, assuming of course that each reaction step has proceeded according to plan.

The diamide substrates were built up on a scaffold containing a thiopyrimidine safety catch linker at the first cleavage site, a diamino ethane connecting group carrying an N-benzyl peak splitting group, and a photolabile linker at the second cleavage site joining the substrate to the diaminoethane connecting group.

An intermediate construct containing the N-benzyl diamino ethane peak splitter group and photolabile pyrimidine linker group was prepared by the reaction sequence shown in Scheme 7 below, the subsequent synthetic steps and preparation of the combinatorial library being shown in Scheme 8. The experimental details for each scheme are set out below and the compound or construct numbers used in the experimentals refer to the construct/compound numbers in the two schemes.

Scheme 7

5

10 Experimental for pyrimidine construct

A solution of 4-(chloromethyl)benzoic acid (3.91 g, 23 mmol), HATU (8.74 g, 23 mmol) and DIPEA (7.95 ml, 46 mmol) in DMF (40 ml) was shaken for 20 min then this solution was added to Argogel resin 1 (1 g, 0.46 mmol), having an average bead diameter of 150 μm and a loading of 0.46 mmol g^{-1} , and the whole was shaken for 5h. The resin was then drained and washed with DMF, DCM, Et_2O , DCM and finally Et_2O . The resin (2) was then dried *in vacuo*.


A slurry of thiourea (8.4 g, 110 mmol) in dioxane (80 ml) and ethanol (20 ml) was added to Resin 2 and the whole heated at 80 $^{\circ}\text{C}$ for 16h. The resin was drained and washed with DMF (x 5), DCM (x 5), Et_2O , DCM and finally Et_2O to give resin 3. The resin was

then dried *in vacuo*.

A solution of methyl-2-(dimethylaminomethylene)-3-oxobutanoate (2.4 g, 13.8 mmol) and triethylamine (0.96 ml, 6.9 mmol) in DMF (100 ml) was added to resin 3 and the whole heated at 80 °C for 16h. The resin was drained hot and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin (4) was then dried *in vacuo*. Resin 4 was then treated with a 1:1 mixture of THF and 2N aq.NaOH (100 ml) and shaken for 2h. The resin was then drained and washed with THF/H₂O, 10% AcOH/THF, THF/H₂O, THF, DMF, DCM, Et₂O, DCM, Et₂O and then dried *in vacuo* to give resin 5.

A solution of PyBOP[®] (3.6 g, 6.9 mmol) and DIPEA (2.4 ml, 25 mmol) in DMF (30 ml) was added to resin 5 (5 g, 2.3 mmol) followed by a solution of 1-benzyl-1-*tert*-butoxycarbonyl-1,2-diaminoethane (0.86 g, 3.5 mmol) and 1-(dideutero benzyl)-1-*tert*-butoxycarbonyl-1,2-diaminoethane (0.86 g, 3.5 mmol) in DMF (1 ml) and the whole shaken for 4 h. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. A solution of 20% aq.TFA in DCM (20%, 30 ml) was then added to the resin and shaken for 2h. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and then shaken with 10% DIPEA in DMF for 10 min. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin (6) was then dried *in vacuo*.

Scheme 8







5 Experimental for Scheme 8

The photolinker acid 11 (0.416 g, 1.47mmol), DIPEA (0.51 ml, 2.94 mmol) and PyBOP (0.765 g, 1.47 mmol) were dissolved in DMF (10ml) and left to stand for 10 mins. This was then added to resin 6 (0.7 g, 0.294 mmol) and shaken for 4 h. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and then shaken with 10% DIPEA in DMF for 10 min. The resin was drained and washed with DMF, DCM, Et₂O, DCM, and finally Et₂O. The resin (7) was then dried *in vacuo*.

General Procedure for the Reductive Amination Step


To a vessel containing 16 Irori MicroKan™ containers (each containing 10 mg, 0.004 mmol resin 7) in DCM (30 ml) was added a pre-mixed solution of the amine (for amounts see the table below) and acetic acid (46 μl , 0.768 mmol) in DCM (2 ml) and shaken for 20 min. To the vessel was then added a mixture of tetramethylammonium borohydride (0.404 mg, 1.54 mmol) and acetic acid (46 μl , 0.768 mmol) in DCM (5 ml) and the vessel shaken for 16 h. The vessels were then drained and the MicroKan (TM) containers washed with DCM, DMF, DCM, and Et₂O (each 3 times).

R1		
A		46 mg
B		64 mg (67 μ l DIPEA also added)
C		78 mg
D		23 mg




5

General Procedure for the Acylation Step with amino acids

To each of 4 vessels containing 16 Irori MicroKan™ containers (each can containing 10 mg, 0.004 mmol resin 8) in DMF (30 ml) was added a solution of PyBOP (333 mg, 0.64 mmol), DIPEA (224 µl, 1.28 mmol) and one of the amino acids (see the table below for amounts) in DMF (5 ml) and the mixture shaken for 16 h. The vessels were then drained and the MicroKan™ containers washed with DMF, DCM, DMF, DCM, and Et2O (each 3 times). To a vessel containing all 64 MicroKan™ containers was then added a solution of piperidine (20%) in DMF and shaken for 3 h. The vessels were then drained and the MicroKan™ containers washed with DMF, DCM, DMF, DCM, and Et2O (each 3 times).

R2		
E	 <chem>O=C(O)CNC(=O)OCC1Cc2ccccc2C3Cc4ccccc4C13</chem>	190 mg



56



F		239mg
G		199 mg
H		208 mg

General Procedure for the Acylation Step with acids

To each of 4 vessels containing 16 Irti MicroKan™ containers (each container
 5 containing 10 mg, 0.004 mmol resin 9) in DMF (30 ml) was added a solution of PyBOP
 (333 mg, 0.64 mmol), DIPEA (224 µl, 1.28 mmol) and one of the acids (see table 3 for
 amounts) in DMF (5 ml) and the mixture shaken for 16 h. The vessels were then drained
 and the MicroKan™ containers washed with DMF, DCM, DMF, DCM, and Et2O (each 3
 times).

10

R3		
I		107 mg
J		74mg

K		96 mg
L		80 mg

General Procedure for the analytical cleavage of resin 10

The resin 10 is treated with a 10% solution of *meta*-chloro-perbenzoic acid (mcpba) in DCM for 4 h. The solution is then removed by filtration and the beads washed with DCM. A single bead from each 64 MicroKan™ container is then treated with a 10% solution of 1-methylpiperazine in DMSO and left to stand for 16 h. The resulting cleaved solution is then subjected to analysis by electrospray mass spectrometry. The mass spectra for the cleaved analytical constructs are shown in the spectra identified in the column headed "Construct Cleavage" in the table below. The mass spectra for the first four monomer combinations are shown in Figures 11 to 14.

General Procedure for the photocleavage of resin 10

A single bead from the each 64 MicroKan™ container is swelled in DMSO (containing 0.2% H₂NNH₂) and then subjected to photolysis for 4 h and the solution subjected to analysis by electrospray mass spectrometry. The mass spectra of the photolysis cleavage products of the library are shown in the spectra identified in the column headed "UV Cleavage" in the table below. The mass spectra for the first four monomer combinations are shown in Figures 15 to 18.

Results

<u>Monomer Combinations</u>			<u>Mass Spec ID</u>	
			<u>UV Cleavage</u>	<u>Construct Cleavage</u>
A	I	E	L993489	L991907
A	I	F	L993490	L991908
A	I	G	L993491	L991909
A	I	H	L993492	L991910
A	J	E	L993493	L991911
A	J	F	L993494	L991912
A	J	G	L993495	L991913
A	J	H	L993496	L991914
A	K	E	L993497	L991915

A	K	F	L993498	L991916
A	K	G	L993499	L991917
A	K	H	L993500	L991918
A	L	E	L993501	L991919
A	L	F	L993502	L991920
A	L	G	L993503	L991921
A	L	H	L993504	L991922
B	I	E	L993505	L991923
B	I	F	L993506	L991924
B	I	G	L993507	L991925
B	I	H	L993508	L991926
B	J	E	L993509	L991927
B	J	F	L993510	L991928
B	J	G	L993511	L991929
B	J	H	L993512	L991930
B	K	E	L993513	L991931
B	K	F	L993514	L991932
B	K	G	L993515	L991933
B	K	H	L993516	L991934
B	L	E	L993517	L991935
B	L	F	L993518	L991936
B	L	G	L993519	L991937
B	L	H	L993520	L991938
C	I	E	L993521	L991939
C	I	F	L993522	L991940
C	I	G	L993523	L991941
C	I	H	L993524	L991942
C	J	E	L993525	L991943
C	J	F	L993526	L991944
C	J	G	L993527	L991945
C	J	H	L993528	L991946
C	K	E	L993529	L991947
C	K	F	L993530	L991948
C	K	G	L993531	L991949
C	K	H	L993532	L991950
C	L	E	L993533	L991951
C	L	F	L993534	L991952
C	L	G	L993535	L991953
C	L	H	L993536	L991954
D	I	E	L993537	L991955
D	I	F	L993538	L991956
D	I	G	L993539	L991957
D	I	H	L993540	L991958
D	J	E	L993541	L991959
D	J	F	L993542	L991960
D	J	G	L993543	L991961
D	J	H	L993544	L991962
D	K	E	L993545	L991963
D	K	F	L993546	L991964
D	K	G	L993547	L991965
D	K	H	L993548	L991966

098694 0259
 098694 0259

D	L	E	L993549	L991967
D	L	F	L993550	L991968
D	L	G	L993551	L991969
D	L	H	L993552	L991970


As can be seen from the mass spectra shown in Figures, when the constructs are cleaved photolytically at the second cleavage site to release substrate, the absence of any readily ionisable group on the substrate means that the mass spectrum does not show a strong molecular ion and hence identification of the substrate is difficult. However, when the constructs to the bead are cleaved at the first cleavage site to release an analytical fragment containing the substrate and sensitising and peak splitting groups, a strong characteristic and readily identifiable split molecular ion is produced, thereby enabling the substrate to be identified. In most cases, the identity of the substrate from the molecular ion in the mass spectrum correlated with the identity predicted from the known synthesis history of the resin beads in each MicroKan™. However, in certain of the reactions, the substrates formed oxidation products under the cleavage conditions used to unlock the safety catch linker but such oxidation products could be readily identified as M+16 ions in the mass spectrum. Thus a further advantage of the constructs of the invention is that it provides a means of determining when a particular reaction has not proceeded according to plan.

The dual linker constructs of the invention allow cleavage to take place either to release an analytical construct containing a mass spectrometric sensitising group, or to release substrate. Thus, the constructs enable QC procedures to be carried out at the single bead level in a manner that would not have been possible if the constructs had contained only a single linker and no mass spectrometric sensitising group.

25 **EXAMPLE 7**

Preparation of a Construct Containing an Alloc Linker at the First Cleavage site

An example of a construct containing an allyloxycarbonyl ("Alloc") linker at the first cleavage site and an acid labile Rink linker at the second cleavage site was prepared according to the reaction scheme shown in Scheme 9. In this example, palladium (0) is used to cleave the allyloxy carbonyl group from the amino group of the diamino ethane group so as to release a free amino group that can then function as a mass spectrometric sensitising group.

Scheme 9**Experimental for Scheme 9****General**

In this section, the compound numbers refer to the compound numbers in Scheme 9.

All washings were carried out fivefold with the quoted solvents. Standard washing procedure A: DMF, DCM, DMF, DCM, Et₂O, DCM and Et₂O, all five fold each.

Commercially available acid 2 (65 mg, 0.115 mmol) (Neosystems) was dissolved in DMF (0.5ml) and to this added DIPEA (40 μ l, 0.23 mmol) followed by HATU (44 mg, 0.115 mmol). This mixture was allowed to stand for 5 mins and then added to commercially available Argogel NH₂ (Resin 1) (50 mg, 0.023mmol), having an average bead diameter of 150 μ m and a loading of 0.46 mmol g⁻¹, and shaken for 2 h. The resin was then drained and washed according to standard washing procedure A and then dried *in vacuo*. The resin was then treated with a solution of DCM, TFA and TES (1 ml, 95:2:5 respectively) for 2h and then washed and drained as above and then this treatment with DCM, TFA and TES was repeated for 1 h. The resin was washed and drained as according to standard washing procedure A to give resin 3.

Resin 3 (50 mg, 0.023 mmol) was then treated with a solution of 4-nitrophenylchloroformate (23mg, 0.115 mmol) in DCM (1 ml) and shaken for 16h. The resin was then quickly drained and washed with DCM and Et₂O to give resin 4. To this
5 was added directly a solution of amines 7 (50 mg, 0.2mmol) and 8 (50 mg, 0.2mmol) and DIPEA (70 μ l, 0.4 mmol) in DCM (1ml) and shaken for 16 h. The resin was then drained and washed according to standard washing procedure A and then dried in vacuo. This resin was then treated with a solution of 20% TFA in DCM (1 ml) and shaken for 2h. The resin was drained, washed with a solution of 10% DIPEA in DMF (2 ml) and then drained and
10 washed according to standard washing procedure A and then dried in vacuo to give resin 5.

Rink acid 9 (65 mg, 0.115 mmol) was dissolved in DMF (0.5 ml) and DIPEA (40 μ l, 0.23 mmol) and HATU (44mg, 0.115 mmol) added and this mixture allowed to stand for 5 min. This solution was then added to resin 5 (25 mg, 0.012 mmol) and shaken for 2h. .
15 The resin was washed and drained as according to standard washing procedure A and dried in vacuo. This resin was then treated with a 20% solution of piperidine in DMF (1 ml) for 1 h. The resin was washed and drained as according to standard washing procedure A and dried in vacuo. Benzoic acid (14 mg, 0.115 mmol) was dissolved in DMF (0.5 ml) and DIPEA (40 μ l, 0.23 mmol) and HATU (44mg, 0.115 mmol) added and this mixture
20 allowed to stand for 5 min. This solution was then added to the resin and shaken for 2h. The resin was washed and drained as according to standard washing procedure A and dried in vacuo to give resin 6

Cleavage of Resin 6: Method 1

Resin 6 (0.5 mg) was swelled in DCM and then $(\text{Ph}_3\text{P})_4\text{Pd}(0)$ (2.7 mg, 2.3E^{-3} mmol) added followed by morpholine (10ml, 0.11 mmol) and the mixture shaken for 1 h. A sample of the liquid was removed and analysed by electrospray mass spectrometry to give an analysis as shown in figure 17. As with the previous examples, the presence of a mass spectrometric sensitising group and a peak splitting group enables a strong molecular ion to be formed and to be readily identified.

Cleavage of Resin 6: Method 2

Resin 6 (0.5 mg) was swelled in a mixture of DMSO, THF and 0.5M HCl (0.5 ml, 2:2:1 respectively) and then $(\text{Ph}_3\text{P})_4\text{Pd}(0)$ (2.7 mg, 2.3E^{-3} mmol) added followed by morpholine (10ml, 0.11 mmol) and the mixture shaken for 1 h. A sample of the liquid was removed and analysed by electrospray mass spectrometry to give an analysis as shown in figure 18.


EXAMPLE 8**Preparation of a Construct Containing an Anthracenyl UV Chromophore**

In order to demonstrate that UV spectrometry can be used to provide accurate quantitative information about the products of solid phase reactions, a construct containing an anthracenyl UV chromophore was prepared according to the synthetic route shown in Schemes 10, 11 and 12 below. The construct was provided with a sulphonamide linker at the first cleavage site and a Rink linker at the second cleavage site, an ethylene diamine chain connecting the two linkers and the two nitrogen atoms of the diamine chain serving as the points of attachment of the UV chromophore and either a peak splitting deuterium labelled benzyl group or an unlabelled benzyl group.


Scheme 10 below illustrates the synthesis of a non-resin bound intermediate construct, Scheme 11 illustrates the attachment of the construct of Scheme 10 to a resin support and subsequent reactions on the resin, and Scheme 12 illustrates the attachment of different substrate groups to the constructs and subsequent cleavage experiments. In the experimental section below, the compound numbers used relate to the compounds identified in Schemes 10, 11 and 12.

Scheme 10

5

**Experimental for Scheme 10**

10

**Preparation of Compound 12 (X = ^1H , ^1H)**


15

Dry triethylamine (25 μl , 0.2 mmol) was added to a solution of the amine (X=H, H) (11) (0.05 mmol) in dry dichloromethane (1 ml). A solution of 2-nitro-4-


methylbenzoatesulfonyl chloride (10) (25 mg, 0.1 mmol) in dry dichloromethane (0.5 ml) was then added dropwise and the mixture stirred for 15 minutes. The solvent was evaporated *in vacuo* and the residue purified by flash chromatography using 2:1 hexane/ethyl acetate as eluent to afford the sulphonamide (12) (23.3 mg, 95%) as a colourless oil, R_f 17/50 [hexane-ethyl acetate (2:1)]; (Found: C, 53.7; H, 5.4; N, 8.4; S, 6.5. $C_{22}H_{27}N_3O_8S$ requires C, 53.5; H, 5.5; N, 8.5; S, 6.5%); δ_H (DMSO- d^6) 1.38 (9H, s, H-18), 3.10 (2H, t, J 8, H-9), 3.24 (2H, t, J 8, H-10), 3.95 (3H, s, O-Me), 4.32 (2H, s, H-11), 7.13-7.32 (5H, m, H-13, 14 and 15), 8.09 (1H, d, J 8, H-6), 8.29 (1H, s, H-3), 8.32 (1H, d, J 8, H-3); δ_C (DMSO- d^6) 28.3 (C-18), 40.2 (C-9 and 10), 46.2 (C-11), 53.2 (O-Me), 79.3 (C-17), 125.1 (C-13), 127.2 (C-14 and 15), 128.6 (C-6), 130.3 (C-13), 133.1 (C-5), 134.4 (C-12), 136.6 (C-1), 147.6 (C-4), 163.7 (C-16 and C=O); MS (Electrospray -ve) m/z 494 (M-H)⁻; HPLC, R_t 6.8 min.

Preparation of Compound 12 (X = 2H , 2H)

Dry triethylamine (25 μ l, 0.2 mmol) was added to a solution of the amine (X = 2H , 2H) (11) (0.05 mmol) in dry dichloromethane (1 ml). A solution of 2-nitro-4-methylbenzoatesulfonyl chloride (10) (25 mg, 0.1 mmol) in dry dichloromethane (0.5 ml) was then added dropwise and the mixture stirred for 15 minutes. The solvent was evaporated *in vacuo* and the residue purified by flash chromatography using 2:1 hexane/ethyl acetate as eluent to afford the sulphonamide (12) (23.5 mg, 94%) as a colourless oil, R_f 17/50 [hexane-ethyl acetate (2:1)]; (Found: C, 53.2; H, 5.6; N, 8.5; S, 6.4. $C_{22}H_{25}D_2N_3O_8S$ requires C, 53.3; H, 5.5; N, 8.5; S, 6.5%); δ_H (DMSO- d^6) 1.40 (9H, s, H-18), 3.05 (2H, m, H-9), 3.20 (2H, dt, J 3 and 13, H-10), 3.9 (3H, s, O-Me), 7.10-7.35 (5H, m, H-13, 14 and 15), 8.09 (1H, d, J 8, H-6), 8.35 (1H, d, J 8, H-5), 8.40 (1H, m, H-8), 8.45 (1H, s, H-3); δ_C (DMSO- d^6) 27.8 (C-18), 40.9 (C-9 and 10), 45.9 (C-11), 53.0 (O-Me), 79.1 (C-17), 124.8 (C-13), 127.0 (C-14 and 15), 128.3 (C-6), 130.0 (C-13), 132.9 (C-5), 134.2 (C-12), 136.4 (C-1), 147.5 (C-4), 154.7 (C-2), 163.5 (C-16 and C=O); MS (Electrospray +ve) m/z 496 (MH)⁺; HPLC, R_t 6.8 min.

Preparation of Compounds 13 and 1**Compound 13**


Di-*tert*-butylazodicarboxylate (32.6 mg, 142 μmol) was dissolved in dry tetrahydrofuran (0.5 ml) under nitrogen and added dropwise to a stirred solution of triphenylphosphine (37.1 mg, 142 μmol), 3-(9-anthracene)propanol (17.6 mg, 74 μmol) and sulphonamide **12** (X=H, H and ^2H , ^2H) (35 mg, 71 μmol), dissolved in dry tetrahydrofuran (1 ml) under nitrogen. After one hour the reaction was deemed complete by tlc and the solution was evaporated to near-dryness. The residue was purified by flash chromatography


**Compound 1**

15


using 2:1 hexane/ethyl acetate containing 10% triethylamine to afford the sulphonamide **13** (45 mg, 90%) as a colourless oil, R_f 15/38 (hexane-ethyl acetate (2:1)); MS (Electrospray +ve) m/z 612, 614 (MH-Boc) $^+$, MS (Electrospray -ve) m/z 756, 758 (M-H+formate) HPLC,

R_f 6.9 min. 2M aqueous sodium hydroxide (0.35 ml, 0.7 mmol) was added dropwise to a solution of the ester **13** (0.25 g, 0.35 mmol) in methanol-1,4-dioxane (4:1) (2 ml). After stirring at room temperature for 1 hour (further methanol-dioxane (ca. 1 ml) was added as necessary to ensure a single phase) sufficient 2M HCl added to render the solution mildly acidic. The solution transferred to a separating flask containing ethyl acetate (50 ml) and water (10 ml) and after partition the aqueous layer was extracted again with ethyl acetate (25 ml). The combined organic extracts were dried (MgSO₄) and evaporated under reduced pressure to afford the acid **1** (0.23 g, 94%) as a colourless oil; R_F 2/40 [hexane-ethyl acetate (2:1)]; δ_H (CDCl₃) 1.40 (9H, br. d, *t*Bu), 1.90 (2H, br. m, CH₂), 3.3-3.7 (8H, br. m, 4xCH₂), 7.10-8.30 (17H, br. m, Arom. H); MS (electrospray +ve) m/z 697, 699 HPLC, R_f 7.2 min.

Scheme 11


Scheme 12

10

Experimental for Schemes 11 and 12

15 Dry aminomethyl Argogel® (0.87 g, 0.35 mmol), having an average bead diameter of 150 μm and a loading of 0.4 mmol g^{-1} , in a reaction vessel flushed with dry nitrogen was swollen with dry dichloromethane (5 ml). In a separate flask flushed with

nitrogen, the benzoic acid (**1**) (0.67 g, 0.93 mmol), PyBOP (0.728 g, 1.4 mmol) and 1-hydroxy-benzotriazole (0.19 g, 1.4 mmol) were dissolved in dry dimethylformamide (2 ml) and the resulting solution stirred two minutes before being transferred to the suspension of resin *via cannula*. A slow stream of nitrogen was aspirated through the solution for five minutes to ensure mixing and diisopropylethylamine (0.49 ml, 2.8 mmol) then added. Agitation was continued for 18 h. whereupon the resin (**2**) was drained, washed (dichloromethane (3x7 ml), dimethylformamide (3x7 ml) and dichloromethane (3x7 ml)) and dried *in vacuo*. An analytical sample of **2** gave a negative Kaiser test.




10

Resin **2** (0.35 mmol) was swollen in dichloromethane (3 ml) and phenol (66 mg, 0.7 mmol) added, followed by trifluoroacetic acid (4.5 ml). The resin was gently agitated for 5 minutes using a stream of nitrogen then drained and washed with dichloromethane (2x5 ml). The process was repeated and, after draining, the resin washed (dichloromethane (3x8 ml), 10% diisopropylamine in dichloromethane (2x6 ml) and dichloromethane (4x8 ml)) and dried *in vacuo*. An analytical sample gave a positive Kaiser test.

The resin, in a reaction vessel flushed with nitrogen, was swollen with dry dichloromethane (5 ml). In a separate flask flushed with nitrogen C-4 RINK acid (0.795 g, 1.4 mmol), PyBOP (1.46 g, 2.8 mmol) and 1-hydroxybenzotriazole (0.378 g, 2.8 mmol) were dissolved in dry dimethylformamide (3 ml) and the resulting solution transferred to the suspension of resin *via cannula*. This mixture was agitated gently by aspirating a stream of nitrogen through the solution and after five minutes dry diisopropylethylamine (0.98 ml, 5.6 mmol) was added. Agitation was continued on a mechanical shaker for 18 h. whereupon the resin (**3**) was drained and washed (dichloromethane (3x8 ml),

dimethylformamide (3x5 ml) and dichloromethane (3x5 ml)) and dried *in vacuo*. An analytical sample gave a negative Kaiser test.



5 A sample of resin 3 (50 mg, 14 μmol) was treated with 20% v/v piperidine in 1:1 dichloromethane/dimethylformamide (2 ml) for 15 minutes. The resin was drained and washed (dichloromethane (3x2 ml), dimethylformamide (3x2 ml) and dichloromethane (3x2 ml)) then dried *in vacuo*, an analytical sample giving a positive bromophenol blue

10 test. The reaction vessel containing the resin was flushed with nitrogen and dry 1:1 dichloromethane /dimethylformamide (0.5 ml) added. In a separate flask flushed with nitrogen PyBOP (57 mg, 110 μmol), 1-hydroxybenzotriazole (15 mg, 110 μmol) and the appropriate acid (**4a-d**) (55 μmol) were dissolved in dry 1:1 dichloromethane-

15 dimethylformamide (0.5 ml) and this solution added in one portion to the suspension of resin, through which a stream of nitrogen was aspirated to ensure uniform mixing. After agitating for 18 h. the resin was drained, washed (dichloromethane (3x2 ml), dimethylformamide (4x2 ml) and dichloromethane (3x2 ml)) and dried *in vacuo* to give resins **5a-d**. An analytical sample of each gave a negative Kaiser test.

20 A small sample of each of the four resins was treated with DBU/ mercaptoethanol in acetonitrile to release **6a-d** which were analysed by HPLC and low-resolution mass spectrometry:

6a (R = 3-dimethylaminobenzoyl) HPLC R_t 4.51 min., MS (electrospray +ve) m/z 843.7 and 845.7;

25 **6b** (R = 2-naphthylacetoyl) HPLC R_t 5.41 min., MS (electrospray +ve) m/z 863.4 and 865.4;

6c (R = 4-pentenoyl) HPLC R_t 4.98 min., MS (electrospray +ve) m/z 778.7 and 780.7;

6d (R = *tert*-Butylacetoyl) HPLC R_t 5.18 min., MS (electrospray +ve) m/z 795.0 and 797.0.

Relative quantitation.

- 5 Approximately equal quantities (ca. 50 mg) of resins **5a** and **5b** were combined and treated with 4-mercaptobenzoic acid (43 mg, 20 μ mol) and morpholine (49 μ mol) in dichloromethane (2 ml). After one hour the solution was drained and the resin washed with dichloromethane (2x1 ml). These combined washings were diluted with ethyl acetate (10 ml) and washed firstly with 50% saturated aqueous sodium bicarbonate (3 ml), water (3 ml)
- 10 and brine (2 ml) and dried over magnesium sulphate. The filtered solution was evaporated to afford approximately 5 mg of a mixture of **6a** and **6b**. The ratio of components in this mixture was assessed firstly by HPLC, measuring peak areas at 254 nm and 386 nm, which was correlated with the ratio determined from the magnitude of the integrations of characteristic resonances in the ^1H NMR spectrum.

15

HPLC analysis

	6a	6b
Area ratio (254 nm)	1.00	1.30
Area ratio (386 nm)	1.00	1.26

^1H nmr analysis

	6a	6b
Ratio	1.00	1.33

20

In the same way a mixture of resins **5c** and **5d**, afforded a mixture of **6c** and **6d**, the ratio of which were again assessed by HPLC and correlated with the ratios measured using ^1H nmr spectroscopy.

25 HPLC analysis

	6c	6d
Area ratio (254 nm)	1.00	0.93
Area ratio (386 nm)	1.00	0.97

¹H nmr analysis

	6c	6d
Ratio	1.00	0.96

Finally, 6a, 6b, 6c and 6d were combined in one solution, which was analysed using HPLC and ¹H nmr as before:

5

HPLC analysis

	6a	6b	6c	6d
Area ratio (254 nm)	0.87	1.35	1.00	1.00
Area ratio (386 nm)	0.84	1.30	1.00	0.99

¹H nmr analysis

	6a	6b	6c	6d
Ratio	0.85	1.34	1.00	1.05

- 10 Resin 3 (214 mg, 59 μ mol) was treated with 20% v/v piperidine in 1:1 dichloromethane/dimethylformamide (3 ml) for 60 minutes. The resin was drained, washed (dichloromethane (3x3 ml), dimethylformamide (3x3 ml) and dichloromethane 93x3 ml)) and dried *in vacuo*, an analytical sample giving a positive bromophenol blue test. The reaction vessel was then flushed with nitrogen and the resin swollen with dry 1:1
- 15 dichloromethane/dimethylformamide (2 ml).

- In a separate flask flushed with nitrogen PyBOP (245 mg, 470 μ mol), 1-hydroxybenzotriazole (64 mg, 470 μ mol) and a mixture of 4-pentenoic acid (6.0 μ l, 59 μ mol), 3-dimethylaminobenzoic acid (19.5 mg, 120 μ mol) and *tert*-butylacetic acid (23 μ l, 180 μ mol) were dissolved in dry 1:1 dichloromethane/dimethylformamide (1 ml) and the solution added in one portion to the suspension of resin. A gentle stream of nitrogen was passed through the mixture and after five minutes diisopropylethylamine (165 μ l, 940 μ mol) was added. After agitating for 18 h. the resin (7) was drained, washed (dichloromethane (3x4 ml), dimethylformamide (4x4 ml) and dichloromethane (3x4 ml))
- 25 and dried *in vacuo*. An analytical sample of 7 gave a negative Kaiser test.

A small sample of the resin 7 was treated with DBU/ mercaptoethanol in

acetonitrile to release a mixture of **6a**, **6c** and **6d** the relative quantities of these components being assessed by HPLC, measuring the peak areas at 254 and 386 nm (table).

A single bead of **7** was then selected and cleaved in the same way. The ratio of the components was again measured using HPLC.

Approximately 200 mg of resin **7** (0.056 μmol) was swollen with dichloromethane and the excess solvent drained away. Phenol (10.5 mg, 0.112 μmol) was added followed by 80% trifluoroacetic acid in dichloromethane such that this added volume constituted one third of the total. After agitating for two hours the pale red solvent was drained into a round-bottomed flask and the resin washed with distilled dichloromethane (3x3 ml). The combined organics were evaporated to dryness to afford a mixture of the primary amides **8a**, **8c** and **8d**. The ratio of these components was assessed by measuring the magnitude of the integration of characteristic resonances in the ^1H nmr spectrum.

HPLC analysis (bulk beads)

	6a	6c	6d
Area ratio (254 nm)	0.71	1.00	0.44
Area ratio (386 nm)	0.71	1.00	0.46

HPLC analysis (single bead)

	6a	6c	6d
Area ratio (254 nm)	0.71	1.00	0.42
Area ratio (386 nm)	0.69	1.00	0.41

^1H nmr analysis

	8a	8c	8d
Ratio	0.74	1.00	0.42

The results set out in the tables above illustrate that there is a remarkably good correlation between the ratios obtained by the UV method and the ratios obtained by the well established and proven method of nmr analysis. Thus, the data demonstrate that UV detection and analysis can be used to provide a very accurate means of giving quantitative

information about the reaction products of solid phase syntheses. Of particular significance is the fact that UV analysis has been shown to provide an accurate means of providing quantitative data even at the single bead level where the amounts of compound available for analysis are of the order of only 1 nanomole.

5


EXAMPLE 9**Preparation of a Construct Containing a Dansyl Group as a UV Chromophore**

A second UV chromophore-containing construct was prepared, but this time including a dansyl group as the chromophore rather than the anthracenyl group. The sequence of steps leading to the construct is shown in Scheme 13 below. As can be seen from Scheme 13, the construct is analogous to the construct of Example 8 in that a sulphonamide linker group provides a first cleavage site to enable release of analytical fragment, and a Rink linker provides a second cleavage site to enable release of substrate.


10

15 However, in this example, the chromophore, rather than being linked to the sulphonamide nitrogen, is attached to a lysine group positioned between the ethylene diamine chain and the Rink linker .

P.03286-01-01288866


Scheme 13**Experimental for Scheme 13**

In the following experimental details, the compound or construct numbers refer to the compounds and constructs identified in Scheme 13.

Preparation of Compound 3a

5

To a stirred solution of 2-nitro-4-methylbenzoatesulfonyl chloride **1** (1.10 g, 3.90 mmol) and triethylamine (0.39 g, 3.90 mmol) in dry dichloromethane (40 ml), was added at 0°C the amine **2a** (1.00 g, 3.9 mmol) in dry dichloromethane (20 ml) over 30 min. The reaction mixture was stirred for a further 2 h at room temperature then concentrated *in vacuo* to give a yellow oil. Purification by chromatography with [MTBE:hexane (1:1)] as eluant followed by recrystallisation from MTBE (5 ml) and hexane (2 ml) furnished *the sulfonamide 3a* (1.53 g, 79%) as white flakes; mp 129-130°C; R_f 0.31 [MTBE:hexane (1:1)]; (Found: C, 53.2; H, 5.6; N, 8.5; S, 6.4. $C_{22}H_{25}D_2N_3O_8S$ requires C, 53.3; H, 5.5; N, 8.5; S, 6.5%); δ_H (DMSO- d_6) 1.40 (9H, s, H-18), 3.05 (2H, m, H-9), 3.20 (2H, dt, J 3 and 13, H-10), 3.9 (3H, s, O-Me), 7.10-7.35 (5H, m, H-13, 14 and 15), 8.09 (1H, d, J 8, H-6), 8.35 (1H, d, J 8, H-5), 8.40 (1H, m, H-8), 8.45 (1H, s, H-3); δ_C (DMSO- d_6) 27.8 (C-18), 40.9 (C-9 and 10), 45.9 (C-11), 53.0 (O-Me), 79.1 (C-17), 124.8 (C-13), 127.0 (C-14 and 15), 128.3 (C-6), 130.0 (C-13), 132.9 (C-5), 134.2 (C-12), 136.4 (C-1), 147.5 (C-4), 154.7 (C-2), 163.5 (C-16 and C=O); MS (Electrospray +ve) m/z 496 (MH)⁺; HPLC (Method A), R_t 6.07 min.

Preparation of Compound 4a


5

The ester **3a** (0.40 g, 0.80 mmol) in methanol (2 ml) was treated with 1M aqueous sodium hydroxide (1.60 ml, 1.60 mmol) and stirred at room temperature for 1 hour. The reaction was then concentrated *in vacuo* and the residue dissolved in water (10 ml) then acidified with 1M hydrochloric acid (1.80 ml, 1.80 mmol) at 0°C. The resulting white precipitate was extracted with dichloromethane (3 x 10 ml). The combined organic extracts were washed with brine, dried (Na₂SO₄) and evaporated under reduced pressure to *the acid 4a* (0.34 g, 88%) as a white solid; mp 143-145°C; R_f 0.58 [MTBE:hexane (1:1)]; δ_{H} (DMSO-d₆) 1.29 (9H, s, H-18), 3.02 (2H, m, H-9), 3.20 (2H, dt, *J* 3 and 13, H-10), 7.10-7.40 (5H, m, H-13, 14 and 15), 8.06 (1H, d, *J* 8, H-6), 8.28 (1H, s, H-3), 8.30 (1H, d, *J* 8, H-3); δ_{C} (DMSO-d₆) 27.9 (C-18), 40.9 (C-9 and 10), 45.9 (C-11), 79.1 (C-17), 124.5 (C-13), 127.1 (C-14 and 15), 128.4 (C-6), 129.5 (C-13), 132.5 (C-5), 139.2 (C-12), 147.3 (C-1), 155.1 (C-4), 164.8 (C-16 and C=O); (Found: MH⁺, 482.156364 C₂₁H₂₃D₂N₃O₈S requires MH⁺, 482.156615); HPLC (Method A), R_t 5.65 min.

20


Preparation of Compound 3b

25



To a stirred solution of 2-nitro-4-methylbenzoatesulfonyl chloride **1** (1.10 g, 3.90 mmol) and triethylamine (0.39 g, 3.90 mmol) in dry dichloromethane (40 ml), was added at 0°C the amine **2b** (0.95 g, 3.9 mmol) in dry dichloromethane (20 ml) over 30 min. The reaction mixture was stirred for a further 3 h at room temperature then concentrated *in vacuo* to give a yellow oil. Purification by chromatography with [MTBE:hexane (1:1)] as eluant followed by recrystallisation from MTBE (5 ml) and hexane (2 ml) furnished *the sulfonamide 3b* (1.51 g, 79%) as white flakes; mp 131-132°C; R_f 0.28 [MTBE:hexane (1:1)]; (Found: C, 53.7; H, 5.4; N, 8.4; S, 6.5. $C_{22}H_{27}N_3O_8S$ requires C, 53.5; H, 5.5; N, 8.5; S, 6.5%); δ_H (DMSO- d_6) 1.38 (9H, s, H-18), 3.10 (2H, t, J 8, H-9), 3.24 (2H, t, J 8, H-10), 3.95 (3H, s, O-Me), 4.32 (2H, s, H11), 7.13-7.32 (5H, m, H-13, 14 and 15), 8.09 (1H, d, J 8, H-6), 8.29 (1H, s, H-3), 8.32 (1H, d, J 8, H-3); δ_C (DMSO- d_6) 28.3 (C-18), 40.2 (C-9 and 10), 46.2 (C-11), 53.2 (O-Me), 79.3 (C-17), 125.1 (C-13), 127.2 (C-14 and 15), 128.6 (C-6), 130.3 (C-13), 133.1 (C-5), 134.4 (C-12), 136.6 (C-1), 147.6 (C-4), 163.7 (C-16 and C=O); MS (Electrospray -ve) m/z 492 (M-H)⁻; HPLC (Method A), R_t 5.99 min.

Preparation of Compound 4b




20

The ester **3b** (0.40 g, 0.80 mmol) in methanol (2 ml) was treated with 1M aqueous sodium hydroxide (1.60 ml, 1.60 mmol) and stirred at room temperature for 1 hour. The reaction was then concentrated *in vacuo* and the residue dissolved in water (10 ml) then acidified with 1M hydrochloric acid (1.80 ml, 1.80 mmol) at 0°C. The resulting white precipitate was extracted with dichloromethane (3 x 10 ml). The combined organic extracts were washed with brine, dried (Na_2SO_4) and evaporated under reduced pressure to *the acid 4b* (0.36 g, 93%) as a white solid; mp 123.7-124.8°C; R_f 0.59 [MTBE:hexane (1:1)]; δ_H (DMSO- d_6) 1.42 (9H, s, H-18), 3.12 (2H, m, H-9), 3.22 (2H, m, H-10), 4.38 (2H, s, H11), 7.18-7.42 (5H, m, H-13, 14 and 15), 8.11 (1H, d, J 8, H-6), 8.39 (1H, d, J 8, H-3);

8.45 (1H, s, H-3); δ_c (DMSO- d_6) 27.8 (C-18), 40.1 (C-9 and 10), 45.9 (C-11), 79.1 (C-17), 124.8 (C-13), 126.9 (C-14 and 15), 128.4 (C-6), 129.9 (C-13), 132.9 (C-5), 135.8 (C-12), 137.9 (C-1), 147.5 (C-4), 153.9 (C-2), 163.7 (C-16 and C=O); MS (Electrospray -ve) m/z 478 (M-H); HPLC (Method A), R_t 5.56 min.

5

Preparation of Compound 5




10

To a suspension of amine resin (Argogel-NH₂) (0.80 g, 0.32 mmol), having a bead diameter of 150 μ m and a loading of 0.4 mmol g⁻¹, in DMF (4 ml) and dichloromethane (4 ml) was added the benzoic acid (**4a**) (0.46 g, 0.96 mmol), and the benzoic acid (**4b**) (0.46 g, 0.96 mmol), followed by PyBOP (0.99 g, 1.92 mmol) and HOBT (0.26 g, 1.92 mmol) followed, 4 min. later by Hünig's base (0.49 g, 3.84 mmol). The reaction was agitated with nitrogen for 18 h and the resin then washed with dichloromethane (6 x 10 ml), DMF (6 x 10 ml), dichloromethane (6 x 10 ml), ether (2 x 10 ml) and dried *in vacuo* to give the **sulfonamide resin 5** (0.94 g, 97%) as a yellow solid; Kaiser test was negative; Bromophenol Blue test was negative.

20


Preparation of Compound 6

25




The protected resin 5 (0.85 g, 0.34 mmol) was suspended in dichloromethane (2 ml) and treated with trifluoroacetic acid (2 x 4 ml) for 5 min. Solvents were removed by filtration and the resin washed with 10% DIPEA solution in DMF (3 x 5 ml), dichloromethane (6 x 5 ml), DMF (6 x 5 ml), dichloromethane (6 x 5 ml), ether (2 x 5 ml). The amine resin was then suspended in DMF (4 ml) and dichloromethane (2 ml) FMoc-Lys(Dde)-OH (0.86 g, 1.62 mmol) was added, followed by PyBOP (0.84 g, 1.62 mmol) and HOBt (0.22 g, 1.62 mmol). After 4 min. Hünig's base (0.42 g, 3.24 mmol) was added. The reaction was agitated with nitrogen for 18 h and the resin then washed with dichloromethane (6 x 10 ml), DMF (6 x 10 ml), dichloromethane (6 x 10 ml), ether (2 x 10 ml) and dried *in vacuo* to give the **sulfonamide resin 6** (0.96 g, 100%) as a yellow solid; Kaiser test was negative; Bromophenol Blue test was negative; Resin loading 99% as estimated by quantitative Fmoc group cleavage.

Preparation of Compound 7



Resin (**6**) (0.93 g, 0.28 mmol) was treated with 20% Piperidine in DMF solution (2 x 5 ml) for 10 min. Solvents were removed by filtration and the resin washed with DMF (6 x 5 ml), dichloromethane (6 x 5 ml), and ether (2 x 4 ml). The resin was suspended in DMF (5 ml) and dichloromethane (5 ml) and the Rink acid **linker** (0.92 g, 1.62 mmol) was added, followed by PyBOP (0.84 g, 1.62 mmol) and HOBt (0.22 g, 1.62 mmol). After 4 min. Hünig's base (0.42g, 3.24 mmol) was added. The reaction was agitated with nitrogen for 3 h and the resin then washed with dichloromethane (6 x 5 ml), DMF (6 x 5 ml), dichloromethane (6 x 5 ml), ether (2 x 3 ml) and dried *in vacuo* to give the **sulfonamide resin 7** (1.02 g, 98%) as a yellow solid; Kaiser test was negative; Bromophenol Blue test was negative; Resin loading 94% as estimated by quantitative Fmoc group cleavage.


Preparation of Compounds 9a-d and 10a-d

Resin (7) (70 mg, 0.02 mmol) was treated with 20% piperidine in DMF solution (2 x 1 ml) for 10 min. Solvents were removed by filtration and the resin washed with DMF (6 x 1 ml), dichloromethane (6 x 1 ml), ether (2 x 1 ml). The resin was suspended in DMF (0.5 ml) and dichloromethane (0.5 ml) and the appropriate acid (**8a-d**) (0.15 mmol) was added, followed by PyBOP (0.08 g, 0.15 mmol) and HOBT (0.02 g, 0.15 mmol). After 4 min. Hünig's base (0.04 g, 0.30 mmol) was added. The reaction was agitated with nitrogen for 3 h and the resin then washed with dichloromethane (6 x 1 ml), DMF (6 x 1 ml), dichloromethane (6 x 1 ml), ether (2 x 1 ml) and dried *in vacuo* to give the *sulfonamide resins 9a-d* as a yellow solid; Kaiser test and Bromophenol Blue test were negative in all four cases.

A small sample of each of the four resins was treated with DBU/Mercaptoethanol in acetonitrile to release **10a-d** which were analysed by low resolution mass spectrometry and RP HPLC (Method A):

- 10a** (R' = Z-Gly-) MS (Electrospray +ve) m/z 961 and 963 (MH)⁺; HPLC, R_t 4.01 min.
10b (R' = Boc-Abu-) MS (Electrospray +ve) m/z 955 and 957 (MH)⁺; HPLC, R_t 4.09 min.
10c (R' = 1-naphthylacetyl-) MS (Electrospray +ve) m/z 938 and 939 (MH)⁺; HPLC, R_t 4.28 min.
10d (R' = Boc-Phe-) MS (Electrospray +ve) m/z 1017 and 1019 (MH)⁺; HPLC, R_t 4.42 min.

Preparation of Compounds 11a-d and 12a-d



5

Resin (**9a-d**) (ca. 70 mg, 0.02 mmol) was treated with 10% hydrazine in DMF solution (3 x 1 ml) for 30 min. Solvents were removed by filtration and each resin washed with DMF (6 x 1 ml), dichloromethane (6 x 1 ml), ether (2 x 1 ml). To each resin portion was then added dansyl chloride (40 mg, 0.15 mmol) and triethylamine (15 mg, 0.15 mmol) in dichloromethane (1 ml). After 4 h reaction time the resins were washed with dichloromethane (6 x 1 ml), DMF (6 x 1 ml), dichloromethane (6 x 1 ml), ether (2 x 1 ml) and dried *in vacuo* to give the *sulfonamide resins 11a-d* as a yellow solid; Kaiser test and Bromophenol Blue test were positive in all four cases.

10

15

A small sample of each of the four resins was treated with DBU/Mercaptoethanol in acetonitrile to release **12a-d** which were analysed by low resolution mass spectrometry and RP HPLC (Method B):

20

12a ($R' = \text{Z-Gly-}$) MS (Electrospray +ve) m/z 1030 and 1032 (MH^+); HPLC, R_t 4.77 min.

12b ($R' = \text{Boc-Abu-}$) MS (Electrospray +ve) m/z 1024 and 1026 (MH^+); HPLC, R_t 4.94 min.

25

12c ($R' = \text{1-naphthylacetyl-}$) MS (Electrospray +ve) m/z 1007 and 1009 (MH^+); HPLC, R_t 5.47 min.

12d ($R' = \text{Boc-Phe-}$) MS (Electrospray +ve) m/z 1086 and 1089 (MH^+); HPLC, R_t 5.82 min.

The foregoing examples are intended merely to illustrate the invention and should not be construed as imposing any limitations on the scope of the claims. It will readily be apparent that numerous alternations and modifications could be made to the constructs illustrated in the examples without departing from the principles underlying this invention and all such modifications and alterations are intended to be embraced by this application.

1. **Introduction**
 2. **Background**
 3. **Methodology**
 4. **Results**
 5. **Discussion**
 6. **Conclusion**
 7. **References**
 8. **Appendix**
 9. **Figure 1**
 10. **Figure 2**
 11. **Figure 3**
 12. **Figure 4**
 13. **Figure 5**
 14. **Figure 6**
 15. **Figure 7**
 16. **Figure 8**
 17. **Figure 9**
 18. **Figure 10**
 19. **Figure 11**
 20. **Figure 12**
 21. **Figure 13**
 22. **Figure 14**
 23. **Figure 15**
 24. **Figure 16**
 25. **Figure 17**
 26. **Figure 18**
 27. **Figure 19**
 28. **Figure 20**
 29. **Figure 21**
 30. **Figure 22**
 31. **Figure 23**
 32. **Figure 24**
 33. **Figure 25**
 34. **Figure 26**
 35. **Figure 27**
 36. **Figure 28**
 37. **Figure 29**
 38. **Figure 30**
 39. **Figure 31**
 40. **Figure 32**
 41. **Figure 33**
 42. **Figure 34**
 43. **Figure 35**
 44. **Figure 36**
 45. **Figure 37**
 46. **Figure 38**
 47. **Figure 39**
 48. **Figure 40**
 49. **Figure 41**
 50. **Figure 42**
 51. **Figure 43**
 52. **Figure 44**
 53. **Figure 45**
 54. **Figure 46**
 55. **Figure 47**
 56. **Figure 48**
 57. **Figure 49**
 58. **Figure 50**
 59. **Figure 51**
 60. **Figure 52**
 61. **Figure 53**
 62. **Figure 54**
 63. **Figure 55**
 64. **Figure 56**
 65. **Figure 57**
 66. **Figure 58**
 67. **Figure 59**
 68. **Figure 60**
 69. **Figure 61**
 70. **Figure 62**
 71. **Figure 63**
 72. **Figure 64**
 73. **Figure 65**
 74. **Figure 66**
 75. **Figure 67**
 76. **Figure 68**
 77. **Figure 69**
 78. **Figure 70**
 79. **Figure 71**
 80. **Figure 72**
 81. **Figure 73**
 82. **Figure 74**
 83. **Figure 75**
 84. **Figure 76**
 85. **Figure 77**
 86. **Figure 78**
 87. **Figure 79**
 88. **Figure 80**
 89. **Figure 81**
 90. **Figure 82**
 91. **Figure 83**
 92. **Figure 84**
 93. **Figure 85**
 94. **Figure 86**
 95. **Figure 87**
 96. **Figure 88**
 97. **Figure 89**
 98. **Figure 90**
 99. **Figure 91**
 100. **Figure 92**
 101. **Figure 93**
 102. **Figure 94**
 103. **Figure 95**
 104. **Figure 96**
 105. **Figure 97**
 106. **Figure 98**
 107. **Figure 99**
 108. **Figure 100**
 109. **Figure 101**
 110. **Figure 102**
 111. **Figure 103**
 112. **Figure 104**
 113. **Figure 105**
 114. **Figure 106**
 115. **Figure 107**
 116. **Figure 108**
 117. **Figure 109**
 118. **Figure 110**
 119. **Figure 111**
 120. **Figure 112**
 121. **Figure 113**
 122. **Figure 114**
 123. **Figure 115**
 124. **Figure 116**
 125. **Figure 117**
 126. **Figure 118**
 127. **Figure 119**
 128. **Figure 120**
 129. **Figure 121**
 130. **Figure 122**
 131. **Figure 123**
 132. **Figure 124**
 133. **Figure 125**
 134. **Figure 126**
 135. **Figure 127**
 136. **Figure 128**
 137. **Figure 129**
 138. **Figure 130**
 139. **Figure 131**
 140. **Figure 132**
 141. **Figure 133**
 142. **Figure 134**
 143. **Figure 135**
 144. **Figure 136**
 145. **Figure 137**
 146. **Figure 138**
 147. **Figure 139**
 148. **Figure 140**
 149. **Figure 141**
 150. **Figure 142**
 151. **Figure 143**
 152. **Figure 144**
 153. **Figure 145**
 154. **Figure 146**
 155. **Figure 147**
 156. **Figure 148**
 157. **Figure 149**
 158. **Figure 150**
 159. **Figure 151**
 160. **Figure 152**
 161. **Figure 153**
 162. **Figure 154**
 163. **Figure 155**
 164. **Figure 156**
 165. **Figure 157**
 166. **Figure 158**
 167. **Figure 159**
 168. **Figure 160**
 169. **Figure 161**
 170. **Figure 162**
 171. **Figure 163**
 172. **Figure 164**
 173. **Figure 165**
 174. **Figure 166**
 175. **Figure 167**
 176. **Figure 168**
 177. **Figure 169**
 178. **Figure 170**
 179. **Figure 171**
 180. **Figure 172**
 181. **Figure 173**
 182. **Figure 174**
 183. **Figure 175**
 184. **Figure 176**
 185. **Figure 177**
 186. **Figure 178**
 187. **Figure 179**
 188. **Figure 180**
 189. **Figure 181**
 190. **Figure 182**
 191. **Figure 183**
 192. **Figure 184**
 193. **Figure 185**
 194. **Figure 186**
 195. **Figure 187**
 196. **Figure 188**
 197. **Figure 189**
 198. **Figure 190**
 199. **Figure 191**
 200. **Figure 192**
 201. **Figure 193**
 202. **Figure 194**
 203. **Figure 195**
 204. **Figure 196**
 205. **Figure 197**
 206. **Figure 198**
 207. **Figure 199**
 208. **Figure 200**
 209. **Figure 201**
 210. **Figure 202**
 211. **Figure 203**
 212. **Figure 204**
 213. **Figure 205**
 214. **Figure 206**
 215. **Figure 207**
 216. **Figure 208**
 217. **Figure 209**

30-11-2000

PG3563-PCT

30 November 2000

GB 009903286

ART 34 AMUT

83

CLAIMS

1. A chemical construct for use in solid phase synthesis comprising a solid support Q having linked thereto via a connecting group Y a substrate R; the connecting group Y having first and second cleavage sites which are orthogonally and selectively cleavable; the second cleavage site being selectively cleavable to release the substrate; and the first cleavage site being located at a position between the second cleavage site and the solid support and being selectively cleavable to release a fragment Fr comprising the substrate and at least a portion of the connecting group Y; characterised in that cleavage of the skeleton of the construct at the first cleavage site forms or introduces on the chemical fragment Fr at the first cleavage site a moiety comprising a sensitising group G which sensitises the chemical fragment Fr to instrumental, e.g. mass spectroscopic, analysis.
2. A chemical construct according to claim 1 wherein the chemical fragment Fr contains a means for imparting a characteristic signature to the mass spectrum of the fragment.
3. A chemical construct according to claim 2 wherein the characteristic signature is provided by incorporating into the fragment Fr a peak splitting isotopic label.
4. A chemical construct according to claim 3 wherein the peak splitting isotopic label is defined one or more isotope pairs selected from $^1\text{H}/^2\text{H}$ (D), $^{79}\text{Br}/^{81}\text{Br}$, $^{12}\text{C}/^{13}\text{C}$, $^{14}\text{N}/^{15}\text{N}$ and $^{16}\text{O}/^{18}\text{O}$.
5. A chemical construct according to any one of claims 2 to 4 wherein the means for imparting a characteristic signature to the mass spectrum of the fragment is located between the first and second cleavage sites.
6. A chemical construct according to any one of the preceding claims wherein the first and second cleavage sites are defined by first and second linker groups L^1 and L^2 .
7. A chemical construct according to claim 6 wherein an spacer group A is interposed between the two linker groups L^1 and L^2 , the spacer group A containing means for imparting a characteristic signature to the mass spectrum of the fragment Fr as defined in any one of claims 2 to 5.

8. A chemical construct according to claim 7 wherein the connecting group Y has the formula L^1-A-L^2 .
- 5 9. A chemical intermediate construct according to claim 8 wherein the group A has the general formula $NH-Alk-NH-X^1$ wherein X^1 is hydrogen or an aralkyl group, and Alk is an alkylene group.
- 10 10. A chemical construct according to any one of the preceding claims wherein the sensitising group G is an ionisable group which is ionisable under mass spectrometric conditions.
- 15 11. A chemical construct according to claim 10 wherein the group G is ionisable to form a positive ion under mass spectrometric conditions, for example electrospray mass spectrometric conditions.
- 20 12. A chemical construct according to any one of the preceding claims wherein the group G is a basic amino group.
- 25 13. A chemical construct according to claim 12 wherein the basic amino group is a primary amino group.
14. A chemical construct according to claim 12 wherein the basic amino group is a tertiary amino group.
- 30 15. A chemical construct according to claim 14 wherein the tertiary amino group is a cyclic amino group.
16. A chemical construct according to claim 15 wherein the cyclic amino group is N-methylpiperazino.
17. A chemical construct according to claim 12 or claim 13 wherein the basic amino group is derived from the photochemical cleavage of a carbamate group.
- 35 18. A chemical construct according to any one of claims 3 to 17 wherein the peak splitting isotopic label is contained within a substituted or unsubstituted alkylene diamine group.

19. A chemical construct according to claim 18 wherein the alkylene diamine group is substituted by an N-benzyl group.
- 5 20. A chemical construct according to claim 19 wherein the N-benzyl group has a methylene group which is substituted with the peak splitting atom deuterium.
- 10 21. A chemical construct according to any one of the preceding claims wherein the first cleavage site is selectively cleavable by one type of chemistry selected from a group of chemistries consisting of cleavage under acid conditions, base catalysed cleavage, oxidative cleavage, reductive cleavage, nucleophilic displacement, cleavage by 1,2 *bis* nucleophiles, electrophilic displacement, and thermal, photochemical and enzymatic cleavage, and the second cleavage site is selectively cleavable by a different type of chemistry selected from the said group.
- 15 22. A chemical construct according to claim 21 wherein the first cleavage site is cleavable by one type of chemistry selected from:
- (i) photochemical cleavage, e.g. photochemical cleavage of a nitrobenzylcarbamate group;
- 20 (ii) oxidation followed by cleavage through nucleophilic displacement, for example oxidation of a thiopyrimidine followed by nucleophilic displacement by an amine (e.g. a secondary amine such as N-methyl piperazine);
- 25 (iii) cleavage of a sulphonamide by nucleophilic displacement, for example by a thiolate nucleophile (e.g. mercaptoethanol in the presence of a strong base such as DBU);
- (vi) cleavage of enamine groups (particularly those containing an enamine moiety conjugated to a carbonyl group; e.g. as 1-[4,4-dimethyl-2,6-dioxo-cyclohexylidene]ethyl amino) with a 1,2-*bis* nucleophile such as hydrazine or hydroxylamine or derivatives thereof; and
- 30 (vii) transition metal catalysed cleavage of allyloxycarbonylamino groups, for example palladium (0) catalysed cleavage of allyloxycarbonylamino groups.
- 35 23. A chemical construct according to claim 22 wherein the second cleavage site is cleaved under acid conditions or by photolysis.

24. A chemical construct according to claim 21 or claim 22 wherein the first cleavage site is defined by a sulphonamide linker group, and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.
- 5
25. A chemical construct according to claim 21 or claim 22 wherein the first cleavage site is defined by a thiopyrimidine linker susceptible to cleavage by oxidation followed by nucleophilic displacement, and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.
- 10
26. A chemical construct according to claim 21 or claim 22 wherein the first cleavage site is defined by a dde group and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions.
- 15
27. A chemical construct according to claim 21 or claim 22 wherein the first cleavage site is cleavable under photochemical conditions and the second cleavage site is defined by a group, such as a Rink linker, which is cleavable under acid conditions.
- 20
28. A chemical construct according to claim 21 or claim 22 wherein the first cleavage site is defined by a group such as allyloxycarbonylamino that can be cleaved by a transition metal such as palladium (0), and the second cleavage site is optionally defined by a group, such as a Rink linker, which is cleavable under acidic conditions
- 25
29. A chemical construct according to claim 21 or claim 22 wherein the first cleavage site is cleaved by oxidation followed by nucleophilic displacement.
- 30
30. A chemical construct according to claim 29 wherein the nucleophile is an amine.
31. A chemical construct according to claim 30 wherein the amine is a cyclic amine such as piperidine.
32. A chemical construct according to any one of the preceding claims wherein the fragment Fr contains a chromophore C^u that facilitates analysis of the fragment Fr by ultraviolet, visible or fluorescence spectrophotometry.
- 35

33. A chemical construct according to claim 32 wherein the chromophore C^u has a principal log E_{max} value of at least 2.5.
34. A chemical construct according to claim 33 wherein the principal log E_{max} value is at least 1.5 times greater than the principal log E_{max} of the substrate R.
35. A chemical construct according to any one of claims 1 to 34, the construct comprising a solid support Q having linked thereto via the connecting group Y the substrate R wherein the fragment Fr comprises the substrate and at least a portion of the connecting group Y, and the said portion contains a chromophore C^u which facilitates analysis of the fragment Fr^u by ultra violet, visible or fluorescence spectroscopy, the chromophore C^u having a principal log E_{max} value of at least 2.5 and wherein (i) the principal log E_{max} value is at least 1.5 times greater than the principal log E_{max} of the substrate R; or (ii), the chromophore C^u has an absorption peak at a wavelength remote from absorptions due to the substrate R.
36. A chemical construct according to any one of claims 1 to 35 comprising a solid support Q having linked thereto via the connecting group Y the substrate R wherein the fragment Fr comprises the substrate and at least a portion of the connecting group Y, and the said portion contains a chromophore C^u which facilitates analysis of the fragment Fr^u by ultra violet, visible or fluorescence spectroscopy, wherein the absorption characteristics of the chromophore C^u and the substrate R are such that at a given measurement wavelength, any errors in measurement of the quantity of substrate R (or any fragment or construct containing the fragment) arising from any overlap between absorption bands due to the chromophore and absorption bands due to the substrate R are less than 10%, preferably less than 5%.
37. A chemical construct according to any one of claims 32 to 36 wherein the chromophore is a group containing an aryl group.
38. A chemical construct according to claim 37 wherein the aryl group is a fused polycyclic aryl group, in which one or more ring carbon atoms are optionally replaced by a heteroatom.
39. A chemical construct according to claim 38 wherein the fused polycyclic aryl group is selected from the group consisting of naphthyl, phenanthrenyl and

anthracenyl groups.

40. A chemical construct according to claim 39 wherein the fused polycyclic aryl group is an anthracenyl group.

41. A chemical construct according to claim 39 wherein the fused polycyclic aryl group is a dansyl (1-dimethylamino-5-naphthylsulphonyl) group.

42. A method of analysing the constructs of any one of the preceding claims; the method comprising cleaving the construct at the first cleavage site to release the chemical fragment Fr, the cleavage reaction generating on the chemical fragment Fr at the cleavage site a group comprising a mass spectrometric sensitising group G (e.g. a group which is ionisable under mass spectroscopic conditions), and then subjecting the chemical fragment to mass spectrometry, e.g. electrospray mass spectrometry.

43. An intermediate chemical construct for use preparing a chemical construct as defined in any one of the preceding claims, the intermediate construct having the formula Q-Y' wherein Q' is a reactive or protected form of the group Q.

44. An intermediate construct of the formula Q-L¹-A^p wherein Q and L¹ are as defined in any one of the preceding claims and A^p is a reactive or protected form of the spacer group A containing a peak splitting isotopic label.

45. An intermediate construct according to claim 44 having the general formula Q-L¹-NH-Alk-NH-X¹ wherein X¹ is hydrogen or an aralkyl group, and Alk is an alkylene group.

46. A method of analysis of a solid phase construct; which method comprises:

- (i) providing a chemical construct comprising a solid support Q having linked thereto via a connecting group Y a substrate R wherein Q, Y and R are as defined in any one of the preceding claims; the connecting group Y having first and second cleavage sites which are orthogonally and selectively cleavable; the second cleavage site being selectively cleavable to release the substrate; and the first cleavage site being located at a position between the second cleavage site and the solid support and being selectively cleavable to release a fragment Fr comprising the substrate and at least a portion of the connecting group Y, wherein

the said portion contains a chromophore C^u which facilitates analysis of the fragment Fr^u by ultra violet, visible or fluorescence spectrophotometry;

(ii) cleaving the connecting group at the first cleavage site to release the fragment Fr; and

5 (iii) subjecting the fragment Fr to ultra violet, visible or fluorescence spectrophotometric analysis to quantify the substrate R.

47. A method of analysis of a solid phase construct; which method comprises:

10 (i) providing a chemical construct comprising a solid support Q (e.g. a resin bead having an average diameter in the range from 90µm to 250µm) having linked thereto via a connecting group Y a substrate R wherein Q, Y and R are as defined in any one of the preceding claims, the substrate R being present on each solid support in an amount of no more than 10 nanomoles, preferably less than 5 nanomoles and more preferably less than 2 nanomoles; the connecting group Y
15 having first and second cleavage sites which are orthogonally and selectively cleavable; the second cleavage site being selectively cleavable to release the substrate; and the first cleavage site being located at a position between the second cleavage site and the solid support and being selectively cleavable to release a fragment Fr comprising the substrate and at least a portion of the connecting group
20 Y, wherein the said portion contains a chromophore C^u which facilitates analysis of the fragment Fr by ultra violet, visible or fluorescence spectrophotometry;

(ii) isolating a solid support, or a plurality of solid supports not exceeding 20 in number (preferably less than 10, more preferably less than 5, e.g. 1 solid support);

25 (iii) treating the solid support(s) to cleave the connecting group at the first cleavage site to release the fragment Fr^u containing the substrate R; and

(iv) subjecting the fragment Fr^u to ultra violet, visible or fluorescence spectrophotometric analysis to quantify the substrate R.

30

48. A method of identifying a pharmaceutically useful substrate comprising preparing a library containing a plurality of chemical constructs as defined in any of the preceding claims, and subjecting the library to biological testing to identify biologically active substrates.

35


49. A method according to claim 48 that includes the further step of formulating a biologically active substrate thus identified with a pharmaceutically acceptable

carrier to form a pharmaceutical composition.

0905340.072504
000229.04290360

1 / 18


FIG. 1
L981994



2 / 18

FIG. 2
L985240

S#: 211-369 RT: 3.19-5.58 AV: 159 NL: 1.77E8
T: + c Full ms [100.00 - 850.00]



3 / 18




FIG. 4
L981290

S#: 197-265 RT: 4.48-5.87 AV: 35 NL: 1.02E7
F: +c Full ms [100.00 - 850.00]




FIG. 5
L981292

S#: 257-289 RT: 5.69-6.24 AV: 17 NL: 1.66E7
F: +c Full ms [185.00 - 850.00]





FIG. 6
L981282


S#: 49-73 RT: 1.02-1.44 AV: 13 NL: 3.83E6
F: +c Full ms [100.00 - 850.00]



7 / 18

FIG. 7
L981287

S#: 273-299 RT: 6.32-6.79 AV: 14 NL 5.76E6
F: +c Full ms [100.00 - 850.00]




8 / 18

FIG. 8

L981297


S#: 215-235 RT: 4.95-5.34 AV: 11 NL: 3.40E6
F: +c Full ms [100.00 - 850.00]



9 / 18

FIG. 9

S#: 151-186 RT: 3.43-4.15 AV: 36 NL: 2.89E8
F: +c Full ms [100.00 - 1500.00]



10 / 18

FIG. 10

S#: 154-190 RT: 3.46-4.21 AV: 37 NL: 3.64E8
F: +c Full ms [100.00 - 1500.00]




FIG. 11
L993489

S# 157-203 RT: 3.92-5.03 AV: 47 NL: 7.61E5
F: +c Full ms [100.00 - 1500.00]



FIG. 12
L993490

S#: 24-52 RT: 0.57-1.23 AV: 29 NL: 5.33E5
F: +c Full ms [100.00 - 1500.00]




FIG. 13
L993491

S#: 24-52 RT: 0.58-1.24 AV: 29 NL: 6.51E5
F: +c Full ms [100.00 - 1500.00]








FIG. 14
L993492










S#: 151-168 RT: 4.26-4.70 AV: 18 NL: 6.47E5
F: +c Full ms [100.00 - 1500.00]

1052/0 04890860

S#: 151-168 RT: 4.29-4.74 AV: 18 NL: 6.52E5
F: +c Full ms [100.00 - 1500.00]



DECLARATION FOR "371" APPLICATION

COMBINED DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION WITH POWER OF ATTORNEYATTORNEY'S DOCKET
PG3565USWFirst Names Inventor:
CARRComplete if known:

App No.:

09/806,840

Filing Date

Group Art Unit:

() Declaration submitted with initial filing or

(x) Declaration submitted after initial filing (surcharge required 37CFR1.16(e))



23347

PATENT TRADEMARK OFFICE

As below named inventor. I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CHEMICAL CONSTRUCTS

the specification of which (check only one item below):

[] is attached hereto.

OR

[X] was filed on _____ as United States application Serial No. _____ or PCT International

Application Number GB99/03286 filed 10/05/1999 and was amended on (MM/DD/YYYY)
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35, U.S.C. §119 (a)-(d) or §365(b) of any foreign applications(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

Prior Foreign Application Number (s)	Country	Foreign Filing Date (MM/DD/YYYY)	PRIORITY CLAIMED
1. GB9821655.9	GB	10/05/1998	x
2.			
3.			
4.			
5.			

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date (MM/DD/YYYY)
2.	
3.	
4.	
5.	

DECLARATION FOR "371" APPLICATION

**COMBINED DECLARATION FOR UTILITY or DESIGN
PATENT APPLICATION WITH POWER OF ATTORNEY** Continued

 ATTORNEY'S DOCKET NUMBER
PG3565USW

I hereby claim the benefit under 35, U.S.C. §120 of any United States application or §365(c) of any PCT international application designating the United States of America that is listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. PARENT APPLICATION or PCT PARENT APPLICATION

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	STATUS (Check one)		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith. (List name and registration number)

David J. Levy Reg. No. 27,655
 Charles E. Dadswell Reg. No. 35,851
 Karen L. Prus Reg. No. 39,337
 Robert H. Brink Reg. No. 36,094
 Elizabeth Selby Reg. No. 38,298

James P. Riek Reg. No. 39,009
 Virginia C. Bennett Reg. No. 37,092
 Frank P. Grassler Reg. No. 31,164
 Christopher P. Rogers Reg. No. 36,334
 Lorie Ann Morgan Reg. No. 38,181

Bonnie L. Deppenbrock Reg. No. 28,209
 John L. Lemanowicz Reg. No. 37,380
 Amy H. Fix Reg. No. 42,616

Send Correspondence to:

David J. Levy, Patent Counsel
Corporate Intellectual Property Department
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709


Direct Telephone Calls to:

Frank P. Grassler
919-483-2482

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	CARR	Robin	Arthur Ellis
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	DATE:
	POST OFFICE ADDRESS	Stevenage	Hertfordshire, GB	COUNTRY OF CITIZENSHIP
2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	GEHANNE	Sylvie	DATE:
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Verona	IT	FR
3	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	KAY	Corinne	DATE:
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Cambridge	GB	FR

DECLARATION FOR "371" APPLICATION

2 0 4	FULL NAME OF INVENTOR	FAMILY NAME McKEOWN	FIRST GIVEN NAME Stephen	SECOND GIVEN NAME/INITIAL Carl
	INVENTOR'S SIGNATURE			DATE:
	RESIDENCE & CITIZENSHIP	CITY Stevenage	STATE OR FOREIGN COUNTRY Hertfordshire, GB	COUNTRY OF CITIZENSHIP GB
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 5	FULL NAME OF INVENTOR	FAMILY NAME MURRAY	FIRST GIVEN NAME Peter	SECOND GIVEN NAME/INITIAL John
	INVENTOR'S SIGNATURE			DATE:
	RESIDENCE & CITIZENSHIP	CITY Birmingham	STATE OR FOREIGN COUNTRY GB	COUNTRY OF CITIZENSHIP GB
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline, Inc. Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 5	FULL NAME OF INVENTOR	FAMILY NAME PAIO	FIRST GIVEN NAME Alfredo	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE			DATE:
	RESIDENCE & CITIZENSHIP	CITY Verona	STATE OR FOREIGN COUNTRY IT	COUNTRY OF CITIZENSHIP IT
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 5	FULL NAME OF INVENTOR	FAMILY NAME SCICINSKI	FIRST GIVEN NAME Jan	SECOND GIVEN NAME/INITIAL Josef
	INVENTOR'S SIGNATURE			DATE: 11 June 2001
	RESIDENCE & CITIZENSHIP	CITY Cambridge GBX	STATE OR FOREIGN COUNTRY GB	COUNTRY OF CITIZENSHIP GB ✓
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 8	FULL NAME OF INVENTOR	FAMILY NAME WATSON	FIRST GIVEN NAME Stephen	SECOND GIVEN NAME/INITIAL Paul
	INVENTOR'S SIGNATURE			DATE:
	RESIDENCE & CITIZENSHIP	CITY Stevenage	STATE OR FOREIGN COUNTRY Hertfordshire, GB	COUNTRY OF CITIZENSHIP GB
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline, Inc. Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 9	FULL NAME OF INVENTOR	FAMILY NAME WILLIAMS	FIRST GIVEN NAME Geoffrey	SECOND GIVEN NAME/INITIAL Martyn
	INVENTOR'S SIGNATURE			DATE:
	RESIDENCE & CITIZENSHIP	CITY Cambridge	STATE OR FOREIGN COUNTRY GB	COUNTRY OF CITIZENSHIP NZ
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 10	FULL NAME OF INVENTOR	FAMILY NAME ZARAMELLA	FIRST GIVEN NAME Alessio	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE			DATE:
	RESIDENCE & CITIZENSHIP	CITY Verona	STATE OR FOREIGN COUNTRY IT	COUNTRY OF CITIZENSHIP IT
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US

DECLARATION FOR "371" APPLICATION

COMBINED DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION WITH POWER OF ATTORNEY

() Declaration submitted with initial filing or

(x) Declaration submitted after initial filing (surcharge required 37CFR1.16(e))

ATTORNEY'S DOCKET
PG3565USWFirst Names Inventor:
CARR**Complete if known:**

App No.:

09/806,840

Filing Date

Group Art Unit:

As below named inventor. I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CHEMICAL CONSTRUCTS

the specification of which (check only one item below):

[] is attached hereto.

OR

[X] was filed on _____ as United States application Serial No. _____ or PCT International

Application Number GB99/03286 filed 10/05/1999 and was amended on (MM/DD/YYYY)
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35, U.S.C. §119 (a)-(d) or §365(b) of any foreign applications(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

Prior Foreign Application Number (s)	Country	Foreign Filing Date (MM/DD/YYYY)	PRIORITY CLAIMED
1. GB9821655.9	GB	10/05/1998	x
2.			
3.			
4.			
5.			

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date (MM/DD/YYYY)
2.	
3.	
4.	
5.	

COMBINED DECLARATION FOR UTILITY or DESIGN PATENT APPLICATION WITH POWER OF ATTORNEY Continued

 ATTORNEY'S DOCKET NUMBER
PG3565USW

I hereby claim the benefit under 35, U.S.C. §120 of any United States application or §365(c) of any PCT international application designating the United States of America that is listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. PARENT APPLICATION or PCT PARENT APPLICATION

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	STATUS (Check one)		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith. (List name and registration number)

David J. Levy	<u>Reg. No. 27,655</u>	James P. Riek	<u>Reg. No. 39,009</u>	Bonnie L. Deppenbrock	<u>Reg. No. 28,209</u>
Charles E. Dadswell	<u>Reg. No. 35,851</u>	Virginia C. Bennett	<u>Reg. No. 37,092</u>	John L. Lemanowicz	<u>Reg. No. 37,380</u>
Karen L. Prus	<u>Reg. No. 39,337</u>	Frank P. Grassler	<u>Reg. No. 31,164</u>	Amy H. Fix	<u>Reg. No. 42,616</u>
Robert H. Brink	<u>Reg. No. 36,094</u>	Christopher P. Rogers	<u>Reg. No. 36,334</u>		
Elizabeth Selby	<u>Reg. No. 38,298</u>	Lorie Ann Morgan	<u>Reg. No. 38,181</u>		

Correspondence to:

David J. Levy, Patent Counsel
Corporate Intellectual Property Department
GlaxoSmithKline,
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709

Direct Telephone Calls to:

Frank P. Grassler
919-483-2482

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<u>CARR</u>	<u>Robin</u>	<u>Arthur Ellis</u>
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	<u>Stevenage GBX</u>	<u>Hertfordshire, GB</u>	<u>GB</u>
2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<u>GEHANNE</u>	<u>Sylvie</u>	<u>DATE: 4/7/01</u>
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	<u>Verona</u>	<u>IT</u>	<u>FR</u>
3	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<u>KAY</u>	<u>Corinne</u>	<u>DATE:</u>
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	<u>Cambridge</u>	<u>GB</u>	<u>FR</u>

DECLARATION FOR "371" APPLICATION

2 0 4	FULL NAME OF INVENTOR	FAMILY NAME McKEOWN	FIRST GIVEN NAME Stephen	SECOND GIVEN NAME/INITIAL Carl
	INVENTOR'S SIGNATURE			<u>DATE:</u>
	RESIDENCE & CITIZENSHIP	CITY Stevenage	STATE OR FOREIGN COUNTRY Hertfordshire, GB	COUNTRY OF CITIZENSHIP GB
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 5	FULL NAME OF INVENTOR	FAMILY NAME MURRAY	FIRST GIVEN NAME Peter	SECOND GIVEN NAME/INITIAL John
	INVENTOR'S SIGNATURE			<u>DATE:</u>
	RESIDENCE & CITIZENSHIP	CITY Birmingham	STATE OR FOREIGN COUNTRY GB	COUNTRY OF CITIZENSHIP GB
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline, Inc. Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
6-00 0 6	FULL NAME OF INVENTOR	FAMILY NAME PAIO	FIRST GIVEN NAME Alfredo	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<i>Alfredo Paio</i>		<u>DATE:</u> <i>11th June 2001</i>
	RESIDENCE & CITIZENSHIP	CITY Verona <i>ITX</i>	STATE OR FOREIGN COUNTRY IT	COUNTRY OF CITIZENSHIP IT ✓
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 7	FULL NAME OF INVENTOR	FAMILY NAME SCICINSKI	FIRST GIVEN NAME Jan	SECOND GIVEN NAME/INITIAL Josef
	INVENTOR'S SIGNATURE			<u>DATE:</u>
	RESIDENCE & CITIZENSHIP	CITY Cambridge	STATE OR FOREIGN COUNTRY GB	COUNTRY OF CITIZENSHIP GB
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 8	FULL NAME OF INVENTOR	FAMILY NAME WATSON	FIRST GIVEN NAME Stephen	SECOND GIVEN NAME/INITIAL Paul
	INVENTOR'S SIGNATURE			<u>DATE:</u>
	RESIDENCE & CITIZENSHIP	CITY Stevenage	STATE OR FOREIGN COUNTRY Hertfordshire, GB	COUNTRY OF CITIZENSHIP GB
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline, Inc. Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 9	FULL NAME OF INVENTOR	FAMILY NAME WILLIAMS	FIRST GIVEN NAME Geoffrey	SECOND GIVEN NAME/INITIAL Martyn
	INVENTOR'S SIGNATURE			<u>DATE:</u>
	RESIDENCE & CITIZENSHIP	CITY Cambridge	STATE OR FOREIGN COUNTRY GB	COUNTRY OF CITIZENSHIP NZ
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US
2 0 10	FULL NAME OF INVENTOR	FAMILY NAME ZARAMELLA	FIRST GIVEN NAME Alessio	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<i>Alessio Zaramella</i>		<u>DATE:</u> <i>18th June 2001</i>
	RESIDENCE & CITIZENSHIP	CITY Verona	STATE OR FOREIGN COUNTRY IT	COUNTRY OF CITIZENSHIP IT
	POST OFFICE ADDRESS	POST OFFICE ADDRESS GlaxoSmithKline Five Moore Drive, PO Box 13398	CITY Research Triangle Park	STATE & ZIP CODE/COUNTRY NC 27709 US

DECLARATION FOR "371" APPLICATION

**COMBINED DECLARATION FOR UTILITY OR DESIGN PATENT
APPLICATION WITH POWER OF ATTORNEY**

() Declaration submitted with initial filing or

(x) Declaration submitted after initial filing (surcharge required 37CFR1.16(e))

ATTORNEY'S DOCKET
PG3565USWFirst Names Inventor:
CARR**Complete if known:**

App No.:

09/806,840

Filing Date

Group Art Unit:

As below named inventor. I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CHEMICAL CONSTRUCTS

the specification of which (check only one item below):

[] is attached hereto.

OR

[X] was filed on _____ as United States application Serial No. _____ or PCT International

 Application Number GB99/03286 filed 10/05/1999 and was amended on (MM/DD/YYYY)
 _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35, U.S.C. §119 (a)-(d) or §365(b) of any foreign applications(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

Prior Foreign Application Number (s)	Country	Foreign Filing Date (MM/DD/YYYY)	PRIORITY CLAIMED
1. GB9821655.9	GB	10/05/1998	x
2.			
3.			
4.			
5.			

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date (MM/DD/YYYY)
2.	
3.	
4.	
5.	

DECLARATION FOR "371" APPLICATION

**COMBINED DECLARATION FOR UTILITY or DESIGN
PATENT APPLICATION WITH POWER OF ATTORNEY** ContinuedATTORNEY'S DOCKET NUMBER
PG3565USW

I hereby claim the benefit under 35, U.S.C. §120 of any United States application or §365(c) of any PCT international application designating the United States of America that is listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. PARENT APPLICATION or PCT PARENT APPLICATION

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	STATUS (Check one)		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith. (List name and registration number)

David J. Levy Reg. No. 27,655
 Charles E. Dadswell Reg. No. 35,851
 Karen L. Prus Reg. No. 39,337
 Robert H. Brink Reg. No. 36,094
 Elizabeth Selby Reg. No. 38,298

James P. Riek Reg. No. 39,009
 Virginia C. Bennett Reg. No. 37,092
 Frank P. Grassler Reg. No. 31,164
 Christopher P. Rogers Reg. No. 36,334
 Lorie Ann Morgan Reg. No. 38,181

Bonnie L. Deppenbrock Reg. No. 28,209
 John L. Lemanowicz Reg. No. 37,380
 Amy H. Fix Reg. No. 42,616

Send Correspondence to:

David J. Levy, Patent Counsel
 Corporate Intellectual Property Department
 GlaxoSmithKline,
 Five Moore Drive, PO Box 13398
 Research Triangle Park, NC 27709

Direct Telephone Calls to:

Frank P. Grassler
 919-483-2482

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	CARR	Robin	Arthur Ellis
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STEVENAGE	Hertfordshire, GB	GB
2-30	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	GEHANNE	Sylvie	DATE: 11th, June 2001
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Verona	IT	FR
2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	KAY	Corinne	DATE:
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Cambridge	GB	FR
3	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	KAY	Corinne	DATE:
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Cambridge	GB	FR

DECLARATION FOR "371" APPLICATION

14-00 0 4	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<i>McKEOWN</i>	<u>Stephen</u>	<u>Carl</u>
	RESIDENCE & CITIZENSHIP	CITY <u>Stevenage</u> <i>GBX</i>	STATE OR FOREIGN COUNTRY <u>Hertfordshire, GB</u>	COUNTRY OF CITIZENSHIP <u>GB</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>GlaxoSmithKline</u> <u>Five Moore Drive, PO Box 13398</u>	CITY <u>Research Triangle Park</u>	STATE & ZIP CODE/COUNTRY <u>NC 27709 US</u>
2 0 5	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<u>MURRAY</u>	<u>Peter</u>	<u>John</u>
	RESIDENCE & CITIZENSHIP	CITY <u>Birmingham</u>	STATE OR FOREIGN COUNTRY <u>GB</u>	COUNTRY OF CITIZENSHIP <u>GB</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>GlaxoSmithKline, Inc.</u> <u>Five Moore Drive, PO Box 13398</u>	CITY <u>Research Triangle Park</u>	STATE & ZIP CODE/COUNTRY <u>NC 27709 US</u>
2 0 5	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<u>PAIO</u>	<u>Alfredo</u>	
	RESIDENCE & CITIZENSHIP	CITY <u>Verona</u>	STATE OR FOREIGN COUNTRY <u>IT</u>	COUNTRY OF CITIZENSHIP <u>IT</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>GlaxoSmithKline</u> <u>Five Moore Drive, PO Box 13398</u>	CITY <u>Research Triangle Park</u>	STATE & ZIP CODE/COUNTRY <u>NC 27709 US</u>
2 0 5	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<u>SCICINSKI</u>	<u>Jan</u>	<u>Josef</u>
	RESIDENCE & CITIZENSHIP	CITY <u>Cambridge</u>	STATE OR FOREIGN COUNTRY <u>GB</u>	COUNTRY OF CITIZENSHIP <u>GB</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>GlaxoSmithKline</u> <u>Five Moore Drive, PO Box 13398</u>	CITY <u>Research Triangle Park</u>	STATE & ZIP CODE/COUNTRY <u>NC 27709 US</u>
8-00 0 8	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<u>WATSON</u>	<u>Stephen</u>	<u>Paul</u>
	RESIDENCE & CITIZENSHIP	CITY <u>Stevenage</u> <i>GBX</i>	STATE OR FOREIGN COUNTRY <u>Hertfordshire, GB</u>	COUNTRY OF CITIZENSHIP <u>GB</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>GlaxoSmithKline, Inc.</u> <u>Five Moore Drive, PO Box 13398</u>	CITY <u>Research Triangle Park</u>	STATE & ZIP CODE/COUNTRY <u>NC 27709 US</u>
2 0 9	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<u>WILLIAMS</u>	<u>Geoffrey</u>	<u>Martyn</u>
	RESIDENCE & CITIZENSHIP	CITY <u>Cambridge</u>	STATE OR FOREIGN COUNTRY <u>GB</u>	COUNTRY OF CITIZENSHIP <u>NZ</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>GlaxoSmithKline</u> <u>Five Moore Drive, PO Box 13398</u>	CITY <u>Research Triangle Park</u>	STATE & ZIP CODE/COUNTRY <u>NC 27709 US</u>
2 0 10	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	<u>ZARAMELLA</u>	<u>Alessio</u>	
	RESIDENCE & CITIZENSHIP	CITY <u>Verona</u>	STATE OR FOREIGN COUNTRY <u>IT</u>	COUNTRY OF CITIZENSHIP <u>IT</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>GlaxoSmithKline</u> <u>Five Moore Drive, PO Box 13398</u>	CITY <u>Research Triangle Park</u>	STATE & ZIP CODE/COUNTRY <u>NC 27709 US</u>

DECLARATION FOR "371" APPLICATION

COMBINED DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION WITH POWER OF ATTORNEYATTORNEY'S DOCKET
PG3565USWFirst Names Inventor:
CARRComplete if known:

App No.:

09/806,840

Filing Date

Group Art Unit:

() Declaration submitted with initial filing or

(x) Declaration submitted after initial filing (surcharge required 37CFR1.16(e))



As below named inventor. I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CHEMICAL CONSTRUCTS

the specification of which (check only one item below):

[] is attached hereto.

OR

[X] was filed on _____ as United States application Serial No. _____ or PCT International

Application Number GB99/03286 ✓ filed 10/05/1999 ✓ and was amended on (MM/DD/YYYY)
_____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35, U.S.C. §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

Prior Foreign Application Number (s)	Country	Foreign Filing Date (MM/DD/YYYY)	PRIORITY CLAIMED
1. GB9821655.9 ✓	GB ✓	10/05/1998 ✓	x
2.			
3.			
4.			
5.			

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date (MM/DD/YYYY)
2.	
3.	
4.	
5.	

DECLARATION FOR "371" APPLICATION

COMBINED DECLARATION FOR UTILITY or DESIGN PATENT APPLICATION WITH POWER OF ATTORNEY Continued				ATTORNEY'S DOCKET NUMBER PG3565USW																
<p>I hereby claim the benefit under 35, U.S.C. §120 of any United States application or §365(c) of any PCT international application designating the United States of America that is listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:</p>																				
PRIOR U.S. PARENT APPLICATION or PCT PARENT APPLICATION																				
U.S. Parent Application or PCT Parent Number		Parent Filing Date (MM/DD/YYYY)		STATUS (Check one)																
				<input type="checkbox"/> PATENTED <input type="checkbox"/> PENDING <input type="checkbox"/> ABANDONED																
<p>POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith. (List name and registration number)</p>																				
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%;">David J. Levy <u>Reg. No. 27,655</u></td> <td style="width: 33%;">James P. Riek <u>Reg. No. 39,009</u></td> <td style="width: 33%;">Bonnie L. Deppenbrock <u>Reg. No. 28,209</u></td> </tr> <tr> <td>Charles E. Dadswell <u>Reg. No. 35,851</u></td> <td>Virginia C. Bennett <u>Reg. No. 37,092</u></td> <td>John L. Lemanowicz <u>Reg. No. 37,380</u></td> </tr> <tr> <td>Karen L. Prus <u>Reg. No. 39,337</u></td> <td>Frank P. Grassler <u>Reg. No. 31,164</u></td> <td>Amy H. Fix <u>Reg. No. 42,616</u></td> </tr> <tr> <td>Robert H. Brink <u>Reg. No. 36,094</u></td> <td>Christopher P. Rogers <u>Reg. No. 36,334</u></td> <td></td> </tr> <tr> <td>Elizabeth Selby <u>Reg. No. 38,298</u></td> <td>Lorie Ann Morgan <u>Reg. No. 38,181</u></td> <td></td> </tr> </table>						David J. Levy <u>Reg. No. 27,655</u>	James P. Riek <u>Reg. No. 39,009</u>	Bonnie L. Deppenbrock <u>Reg. No. 28,209</u>	Charles E. Dadswell <u>Reg. No. 35,851</u>	Virginia C. Bennett <u>Reg. No. 37,092</u>	John L. Lemanowicz <u>Reg. No. 37,380</u>	Karen L. Prus <u>Reg. No. 39,337</u>	Frank P. Grassler <u>Reg. No. 31,164</u>	Amy H. Fix <u>Reg. No. 42,616</u>	Robert H. Brink <u>Reg. No. 36,094</u>	Christopher P. Rogers <u>Reg. No. 36,334</u>		Elizabeth Selby <u>Reg. No. 38,298</u>	Lorie Ann Morgan <u>Reg. No. 38,181</u>	
David J. Levy <u>Reg. No. 27,655</u>	James P. Riek <u>Reg. No. 39,009</u>	Bonnie L. Deppenbrock <u>Reg. No. 28,209</u>																		
Charles E. Dadswell <u>Reg. No. 35,851</u>	Virginia C. Bennett <u>Reg. No. 37,092</u>	John L. Lemanowicz <u>Reg. No. 37,380</u>																		
Karen L. Prus <u>Reg. No. 39,337</u>	Frank P. Grassler <u>Reg. No. 31,164</u>	Amy H. Fix <u>Reg. No. 42,616</u>																		
Robert H. Brink <u>Reg. No. 36,094</u>	Christopher P. Rogers <u>Reg. No. 36,334</u>																			
Elizabeth Selby <u>Reg. No. 38,298</u>	Lorie Ann Morgan <u>Reg. No. 38,181</u>																			
Send Correspondence to: <u>David J. Levy, Patent Counsel</u> <u>Corporate Intellectual Property Department</u> <u>GlaxoSmithKline</u> <u>Five Moore Drive, PO Box 13398</u> <u>Research Triangle Park, NC 27709</u>				Direct Telephone Calls to: <u>Frank P. Grassler</u> <u>919-483-2482</u>																
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.</p>																				
1	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL																
	INVENTOR'S SIGNATURE	CARR	Robin	Arthur Ellis																
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP																
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY																
		Stevenage	Hertfordshire, GB	GB																
		GlaxoSmithKline	Research Triangle Park	NC 27709 US																
		Five Moore Drive, PO Box 13398																		
2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL																
	INVENTOR'S SIGNATURE	GEHANNE	Sylvie																	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP																
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY																
		Verona	IT	FR																
		GlaxoSmithKline	Research Triangle Park	NC 27709 US																
		Five Moore Drive, PO Box 13398																		
3	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL																
	INVENTOR'S SIGNATURE	KAY	Corinne																	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP																
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY																
		Cambridge GBX	GB	FR ✓																
		GlaxoSmithKline	Research Triangle Park	NC 27709 US																
		Five Moore Drive, PO Box 13398																		

DECLARATION FOR "371" APPLICATION

2 0 4	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	McKEOWN	Stephen	Carl
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Stevenage	Hertfordshire, GB	GB
		POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
		GlaxoSmithKline	Research Triangle Park	NC 27709 US
		Five Moore Drive, PO Box 13398		
2 0 5	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	MURRAY	Peter	John
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Birmingham GBX	GB	GB
		POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
		GlaxoSmithKline, Inc.	Research Triangle Park	NC 27709 US
		Five Moore Drive, PO Box 13398		
2 0	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	PAIO	Alfredo	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Verona	IT	IT
		POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
		GlaxoSmithKline	Research Triangle Park	NC 27709 US
		Five Moore Drive, PO Box 13398		
2 0	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	SCICINSKI	Jan	Josef
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Cambridge	GB	GB
		POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
		GlaxoSmithKline	Research Triangle Park	NC 27709 US
		Five Moore Drive, PO Box 13398		
2 0 8	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	WATSON	Stephen	Paul
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Stevenage	Hertfordshire, GB	GB
		POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
		GlaxoSmithKline, Inc.	Research Triangle Park	NC 27709 US
		Five Moore Drive, PO Box 13398		
2 0 9	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	WILLIAMS	Geoffrey	Martyn
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Cambridge GBX	GB	NZ
		POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
		GlaxoSmithKline	Research Triangle Park	NC 27709 US
		Five Moore Drive, PO Box 13398		
2 0 10	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME/INITIAL
	INVENTOR'S SIGNATURE	ZARAMELLA	Alessio	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	Verona	IT	IT
		POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
		GlaxoSmithKline	Research Triangle Park	NC 27709 US
		Five Moore Drive, PO Box 13398		